[STUDY_ID_REMOVED]  
Study ID: RGH‐MD‐54 
 
Title:  A Phase 3, Randomized,  Double‐Blind, Placebo‐Controlled,  Parallel‐Group, Multicenter,  Fixed‐
Dose Clinical Trial  Evaluating  The Efficacy, Safety And Tolerability  Of Cariprazine  In Patients With  
Bipolar I Depression  
 
 
Protocol Amendment  2 Date: 17‐Feb‐2016  
 
 
 
1.0 TITLE PAGE
Forest Laboratories, LLC, an Allergan Affiliate
Harborside Financial Center, Plaza V
Jersey City, NJ 07311
A PHASE 3, RANDOMIZED, DOUBLE -BLIND, PLACEBO -CONTROLLED, 
PAR ALLEL -GROUP, MULTICENTER, FIXED- DOSE CLINICAL TRIAL 
EVALUATING THE EFFICACY, SAFETY AND TOLERABILITY OF 
CARIPRAZINE IN PAT IENTS WITH BIPOLAR I DEPRESSION
RGH -MD-54
IND #77,726
Original Protocol Date : 12 Nov 2015
Amendment #1 Date : 02 Feb 2016
Amendment #2 Date : 17Feb2016
Confidentiality Statement
This document is the property of Forest Laboratories, LLC, an Allergan Affiliate , and 
may not —in full or part —be passed on, reproduced, published, distributed, or submitted 
to any regulatory authority without the express written permission of Forest 
Laboratories, LLC . 
Forest Laboratories, LLC Page 1 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
2.0 SYNOPSIS AND SCHEDULE OF EVALUATIONS
CLINICAL STUDY SYNOPSIS: Study RGH -MD-54
Title of StudyA Phase 3, Randomized, Double-Blind, Placebo -Controlled, Par allel-Group, 
Multicenter, Fixed -Dose Clinical Trial Evaluating the Efficacy, Safety and 
Tolerability of Cariprazine in Patients with Bipolar I Depression
Study Centers (Country) Approximately 85 study centers (United States, non -United States)
Development Phase 3
ObjectiveTo evaluate the efficacy, safety, and tolerability of cariprazine 1.5 mg/day 
and 3.0 mg/day relative to placebo in patients with bipolar I depression
MethodologyMulticenter, randomized, double -blind, placebo -controlled, parallel -group, 
fixed -dose study
Number of Patients 480planned (approximately 160 per treatment group)
Diagnosis and 
Main Criteria for InclusionMale and female outpatients who are 18to 65years of age, meet Diagnostic 
and Statistical Manual of Mental Disorders , Fifth Edition (DSM -5)criteria 
for bipolar I disorder without psychotic features confirmed by the 
administration of the Mini International Neur opsychiatric Interview (MINI ), 
with a current major depressive episode of at least 4 weeks and not exceeding 
12 months in duration, a minimum score of 20 on the 17 -item Hamilton 
Depression Rating Scale (HAMD-17), a minimum score of 2 on item 1ofthe 
HAMD -17, and a minimum score of 4 on the Clinical Global Impressions -
Severity Scale (CGI -S) at Visit 1. 
Test Product, Dosage ,and Mode of 
AdministrationCariprazine 1.5 mg/d ayand 3 .0mg/d aycapsules, oral administration
Duration of TreatmentA no -drug screening period of approximately 7 -14 days, followed by 6 weeks 
of double -blind treatment and a 1-week, no investigational product safet y 
follow -up period.
Reference Therapy, Dos age, and 
Mode of Adm inistrationMatching p lacebo capsules , oral administration
Criteria for Evaluation
Primary Outcome Measure Montgomery -Åsberg Depression Rating Scale (MADRS)
Secondary Outcome Measure CGI-S
 
 
 
 
 
 
 
 
  
Forest Laboratories, LLC Page 2 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

Statistical MethodsThe primary efficacy parameter will be the change from baseline to Week 6 
in MADRS total score. The primary analysis will be performed using a 
mixed-effects mo del for repeated measures (MMRM) with treatment group, 
study center, visit, and treatment group –by-visit interaction as fixed effects 
and the baseline value and baseline by -visit interaction as covariates. An 
unstructured covariance matrix will be used to model the covariance of 
within -patient scores. 
The secondary efficacy parameter will be the chan ge from baseline to Week 6 
in CGI -S score. The secondary efficacy parameter will be analyzed using an 
MMRM as used for the primary analysis.
Matched parallel gatekeeping procedure will be used to control the overall 
type I error rate for multiple compariso ns of the 2 cariprazine dose groups 
(1.5mg/day or 3.0 mg/day) with placebo at Week 6 for the primary and 
secondary efficacy parameters. Statistical significance will be determined by 
comparing the adjusted p -values to α = 0.050.
 
 
 
 
  
Forest Laboratories, LLC Page 3 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
Forest Laboratories, LLC Page 4 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
Forest Laboratories, LLC Page 5 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

3.0 OVERALL TABLE OF CONTENTS 
 
 Page
1.0 TITLE PAGE ............................................................................................. . 
2.0 SYNOPSIS AND SCHEDULE OF EVALUATIONS .............................. . 
3.0 OVERALL TABLE OF CONTENTS ....................................................... . 
3.1 LIST OF IN-TEXT FIGURES................................................................ . 
3.2 LIST OF IN-TEXT TABLES ................................................................. . 
4.0 LIST OF ABBREVIATIONS .................................................................... . 
5.0 ETHICAL CONSIDERATIONS ............................................................... . 
5.1 INSTITUTIONAL REVIEW BOARD AND INDEPENDENT 
ETHICS COMMITTEE ............................................................................... . 
5.2 ETHICAL CONDUCT OF THE STUDY .............................................. . 
5.3 PATIENT INFORMATION AND INFORMED CONSENT ................ . 
6.0 INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE ..................................................................................................
. 
7.0 INTRODUCTION ..................................................................................... . 
8.0 STUDY OBJECTIVES .............................................................................. . 
9.0 INVESTIGATIONAL PLAN .................................................................... . 
9.1 OVERALL STUDY DESIGN A ND PLAN: DESCRIPTION .............. . 
9.2 DISCUSSION OF STUDY DESIGN, INCLUDING THE CHOICE OF CONTROL GROUPS ............................................................................
. 
9.3 SELECTION OF STUDY POPULATION ............................................ . 
9.3.1 Inclusion Criteria .............................................................................. . 
9.3.2 Exclusion Criteria ............................................................................. . 1
2
6
121314
16
16
16
17
18
19
2324
24
25
26
26
27 
Forest Laboratories, LLC Page 6 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
9.3.3 Removal of Patients from Therapy or Assessment .......................... . 
9.3.4 Patient Replacement Procedures ...................................................... . 
9.4 TREATMENTS ...................................................................................... . 
9.4.1 Treatments Administered ................................................................. . 
9.4.2 Identity of Investigational Product(s) ............................................... . 
9.4.3 Method of Assigning Patients to Treatment Groups ........................ . 
9.4.4 Selection of Dosages in the Study .................................................... . 
9.4.5 Selection and Timing of Dose for Each Patient ............................... . 
9.4.6 Blinding ............................................................................................ . 
9.4.7 Unblinding ........................................................................................ . 
9.4.8 Prior and Concomitant Therapy ....................................................... . 
9.4.9 Monitoring Treatment Compliance .................................................. . 
9.5 EFFICACY AND SA FETY VARIABLES ............................................ . 
9.5.1 Diagnostic and Efficacy Assessments .............................................. . 
9.5.1.1 Diagnostic Assessment .............................................................. . 
9.5.1.2 Primary Efficacy Assessment .................................................... . 
9.5.1.3 Secondary Efficacy Assessment ................................................ . 
  
9.5.2.1 Adverse Events ..........................................................................
. 
9.5.2.2 Causality Assessment................................................................. . 
9.5.2.3 Severity Assessment .................................................................. . 
9.5.2.4 Serious Adverse Events ............................................................. . 32
3233
33
33333435
36
36373839
39
39393940
40
40414242 
Forest Laboratories, LLC Page 7 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

9.5.2.5 Reporting Adverse Events and Serious Adverse Events ........... . 
9.5.2.6 Immediate Reporting of Seri ous Adverse Events and Events 
of Special Interest .................................................................................. . 
9.5.2.7 Reporting of Pregnancies Occurring During the Study ............. . 
9.5.2.8 Potential Hy’s Law Cases .......................................................... . 
 .......................................... . 
       
9.5.3 Investigational Product Concentration Measurements .....................
. 
9.5.4 Health Economic and Outcomes Research Assessments ................. . 
9.5.5 Schedule of Assessments ................................................................. .      
9.6 DATA QUALITY 
ASSURANCE.......................................................... . 
9.6.1 Data Monitoring ............................................................................... . 43
44
45
46464848
49
49494950
51
51515153
53
54555656 
Forest Laboratories, LLC Page 8 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

9.6.2 Data Recording and Documentation ................................................ . 
9.7 STATISTICAL METHODS AND DETERMINATION OF 
SAMPLE SIZE ............................................................................................. . 
9.7.1 Patient Populations ........................................................................... . 
9.7.1.1 Screened Population ................................................................... . 
9.7.1.2 Randomized Population ............................................................. . 
9.7.1.3 Safety Population ....................................................................... . 
9.7.1.4 Intent-to-Treat Population .......................................................... . 
9.7.2 Patient Disposition ........................................................................... . 
9.7.3 Demographics and Other Baseline Characteristics .......................... . 
9.7.4 Extent of Exposure and Treatment Compliance .............................. . 
9.7.4.1 Extent of Exposure ..................................................................... . 
9.7.4.2 Measurement of Treatment Compliance .................................... . 
9.7.5 Efficacy Analyses ............................................................................. . 
9.7.5.1 Primary Efficacy Parameters ..................................................... . 
9.7.5.2 Secondary Efficacy Parameters ................................................. . 
 ................................................. . 
      56
57
57
57575757
57
58585859
59
60616162
62
64646565 
Forest Laboratories, LLC Page 9 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

9.7.6.6 Investigational Product Plas ma Concentration Parameters ....... . 
9.7.7 Health Economics and Outc omes Research Analyses ..................... . 
9.7.8 Interim Analysis ............................................................................... . 
9.7.9 Determination of Sample Size .......................................................... . 
9.7.10 Computer Methods ......................................................................... . 
9.8 CHANGES IN THE CONDUCT OF THE STUDY OR PLANNED 
ANALYSES ................................................................................................. . 
9.9 PROTOCOL DEVIATI ONS AND VIOLATIONS ............................... . 
10.0 STUDY SPONSORSHIP......................................................................... . 
10.1 STUDY TERMINATION .................................................................... . 
10.2 REPORTING AND PUBLICATION .................................................. . 
11.0 INVESTIGATOR OBLIGATIONS ........................................................ . 
11.1 DOCUMENTATION ........................................................................... . 
11.2 PERFORMANCE ................................................................................. . 
11.3 USE OF INVESTIGATIONAL MATERIALS ................................... . 
11.4 CASE REPORT FORMS ..................................................................... . 
11.5 RETENTION AND REVIEW OF RECORDS .................................... . 
11.6 PATIENT CONFIDENTIALITY......................................................... . 
12.0 INVESTIGATOR’S STATEMENT ........................................................ . 
13.0 APPENDICES ......................................................................................... . 
APPENDIX I. ELEMENTS OF INFORMED CONSENT .......................... . 
APPENDIX II. CONTACT INFORMATION ............................................. . 
APPENDIX III. CONCOMITANT MEDICATIONS ................................. . 66
6666
67
67
67
6869
69697070
70
71717172
73
74747677 
Forest Laboratories, LLC Page 10 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
APPENDIX IV. MONTGOMERY-ÅSBERG DEPRESSION RATING 
SCALE.......................................................................................................... . 
 
 
APPENDIX VII. CLINICAL GL
OBAL IMPRESSIONS–SEVERITY ...... . 
 
 
  
 
 
 
 
14.0 LITERATURE CITED ............................................................................
. 
 83
89
92
95
96
99
102104
107
110
118 
Forest Laboratories, LLC Page 11 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

3.1 LIST OF IN-TEXT FIGURES 
 
 Page
 
  
Forest Laboratories, LLC Page 12 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

3.2 LIST OF IN-TEXT TABLES 
 
 Page
Table 9.4.5–1. Blister Card C onfiguration and Dosing Regimen .................... . 
 36 
Forest Laboratories, LLC Page 13 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
4.0 LIST OF ABBREVIATIONS
AE adverse event
AIMS Abnorm al Involuntary Movement Scale
ALT alanine aminotransferase
ANCOVA analysis of covariance
AST aspartate aminotransferase
BARS Barnes Akathisia Rating Scale
β-hCG β-human chorionic gonadotropin
BMI body mass index
BP blood pressure
CFR Code of Federal Regulations
CGI-S Clinical Global Impressions –Severity
C-SSRS Columbia –Suicide Severity Rating Scale
DHHS Department of Health and Human S ervices
DSM -5 Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition
ECG electrocardiogram ,electrocardiographic
eCRF electronic case r eport form
EDC electronic data capture
EPS extrapyramidal symptom
ET early termination
FDA Food and Drug Administration
FR Federal Register
GCP good clinical practice
HAM -A Ham ilton Rating Scale for Anxiety
HAMD- 17 17-item Hamilton Depression Rating Scale
HIPAA Health Insurance Portability and Accountability Act of 1996 
Forest Laboratories, LLC Page 14 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
ICF informed consent form
ICH Internat ional Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IND Investigational New Drug (application)
IRB Institutional Review Board
ITT intent totreat
IxRS Interactive Vo ice/Interactive Web Response System
MADRS Montgomery -Åsberg Depression Rating Scale
MMRM mixed -effects model for repeated measures
NA not applicable
NDA New  Drug Application
PCS potentially clinically significant
PI principal investigator
PID patient identification
PRN as needed ( pro re nata )
QIDS -SR16 Quick Inventory of Depressive Symptomatology –Self-Report
QTc QT interval correct for heart rate
QTcB QT interval corrected for heart rate using the Bazett formula 
QTcF QT interval corrected for heart rate using the Fridericia formula 
RSM Regional Site Manager
SAE serious adverse event
SAS Simpson -Angus Scale
TEAE treatment -emergent adverse event
ULN upper limit of normal
YMRS Young Mania Rating Scale 
Forest Laboratories, LLC Page 15 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

5.0 ETHICAL CONSIDERATIONS
This clinical study  is designed to comply  with the International Conference on 
Harmonisation ( ICH)Guidance on General Considerations for Clinical Trials (I CH-E8; 
62 FR 66113, 17 Dec 1997) and Good Clinical Practice (GCP) (ICH E6; 62 FR 25692, 
09May 1997) .
5.1 INSTITUTIONAL REVIEW BOARD AND INDEPENDENT
ETHICS COMMITTEE
United States
Approval b y the Institutional Review Board (I RB) before the start of the study  will be the 
responsibility  of the investigator. A copy  of the approval letter will be supplied to the 
Sponsor ,along with a roster of IRB members or theUSDepartment of Health and 
Human Services (DHHS ) general assurance number . During the course of the study , the 
investigator will provide timely  and accurate reports to the I RB on the progress of the 
study , at intervals not exceeding 1 year (or as appropriate), and will notify  the I RB of 
serious adverse events (SAEs) or other significant safet y findings . The study  protocol, 
informed consent form (ICF) , information sheet advertisements, and amendments (if any ) 
will be approved b y the IRBs at thestudy  center sin conformance with the US Code of 
Federal Regulations (CFR), Title 21, Part 56.
Outside the United States
This study  will be carried out in full compliance with the guidelines of the independent 
ethics committee (IEC) and government agencies of each respective country as well as 
the European Union Clinical Trial Directive (Directive 2001/20/EC), where applicable. 
Before the s tudy begins, the site will require approval from an IEC and government 
agency . During the course of the study , the Sponsor or authorized representative will 
provide timely  and accurate reports to the IEC on the progress of the study , at intervals 
not excee ding 1 year (or as appropriate) and will notify  the IEC of SAEs or other 
significant safet y findings. The study protocol, I CF, information sheet advertisements, 
and amendments (if an y) will be approved b y the IEC at the study  site in conformance 
with CFR, Title 21, Part 56, the European Union Clinical Trial Directive 
(Directive 2001/20/EC), and local regulations.
5.2 ETHIC ALCONDUCT OF THE STUDY
The study  will be conducted in full compliance with US Food and Drug Administration 
(FDA) guidelines for GCP and in a ccordance with the ethical principles that have their 
origins in the Declaration of Helsinki and 21 CFR § 312.120. 
Forest Laboratories, LLC Page 16 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
5.3 PATIENT INFORMATION AND INFORMED CONSENT
Patients, after being given an explanation of the study , will give voluntary  and written 
informed consent and HIPAA (Health Insurance Portability  and Accountability  Act of 
1996) authorization (in compliance with 21 CFR, Parts 50 and 312) , data protection 
consent (Europe only ), or other written documentation in accordance with the relevant 
country  and l ocal privacy requirements (where applicable) before participating in any  
study -related procedures.
Each patient will read and sign an instrument of informed consent and the HI PAA 
authorization form (in countries where applicable) , data protection consent ( Europe onl y), 
or other written documentation in accordance with the relevant country  and local privacy  
requirements (where applicable) after having had an opportunity  to discuss them with the 
principal investigator (PI)before signing; each patient will be made aware that he or she 
may withdraw from the study  at an y time.
The informed consent statement contains all the elements of informed consent listed in 
Appendix I  of the protocol; the HI PAA authorization contains all the core elements and 
mandatory  statements as defined in the CFR. Signed copies of the ICF and the HI PAA 
authorization form or other locally applicable form will be given to the patient, and both 
documents will be placed in the PI ’s study  files. A unique patient identification (PI D) 
number w ill be assigned according to Section 9.4.3 at the time the patient signs the ICF. 
Forest Laboratories, LLC Page 17 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
6.0 INVESTIGATORS AND ST UDY ADMINISTRATIVE 
STRUCTURE
This study  will be performed at a pproximately 85 study center s.
The investigator is responsible for ensuring that an investigation is conducted according 
to the signed investigator statement, the investigational plan, GCP guidelines, and 
applicable regulations; for protecting the rights, safety , and welfare of patients under the 
investigator’s care; and for the control of investigational product sunder investigation. An 
investigator shall obtain the informed consent of each human patient prior to the patient
enrolling in the stud y and/or prior to participating in any  study -related activity . 
The investigator at each sitemust meet their obligations to the patient s, ethics committee, 
Sponsor ,and regulatory  authorities by  maintaining oversight and control of the study ’s 
conduct and the stu dy staff. It is the responsibility  of the investigator to ensure that an y 
and all delegated duties be assigned to qualified staff b y education, experience ,and 
licensure (in accordance with local regulations) and that the investigator oversight is
document ed and assessment of their capabilities and performance consistent with the
study  investigational plan. The investigator at each sitewill be responsible for the 
management of the stud y, including maintaining the study  file and the patient records, 
corresp onding with the IRB, and completing the electronic case report forms (eCRFs).
The following information can be found on FDA Form 1572 and/or study  contacts page 
and/or Trial Master File: Name and contact information of sponsor study  personnel and 
Emergency Telephone Numbers; name, address, and statement of qualifications of each 
investigator; name of each subinvestigator working under the supervision of the 
investigator; name and address of the research facilities to be used; name and address of 
each review ing IRB; US 21 CFR 312.23 section 6(iii)b. 
Forest Laboratories, LLC Page 18 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
7.0 INTRODUCTION
Bipolar disorder is a complex, chronic illness causing dramatic mood swings and unusual 
shifts in energy and behavior, ultimately  resulting in functional impairments. I t manifests 
itself as alterations in mood and energy  from euphoria and excitability  (mania or 
hypomania) to depression and psy chomotor retardation ( Goodwin and Jamison, 1990 ) 
and is associated with significant morbidity  and mortality . Bipolar disorder in the 
United States affec ts 5.7 million adults or about 2.6% of the population 18 y ears and 
older in an y given year (Kessler et al, 2005 ) and has a considerable economic effect on 
our societ y (Wyatt and Henter, 1995). In the y ear 2000, this disorder ranked as the 
seventh leading c ause of worldwide nonfatal disease burden ( World Health Organization, 
2001). Suicide rates within this population are among the highest of all psychiatric 
illnesses (Muller -Oerlinghausen et al, 200 2).
The depressive phase of bipolar disorder causes significantly  more morbidity  and 
mortality  than the manic or hy pomanic phase. Patients with bipolar disorder experience 
depressive s ymptoms much more frequentl y than manic or h ypomanic s ymptoms 
(Hlastala et al, 1997 ; Judd etal, 2002, 2003; Keller et al, 1 986; Post, 2005; Post et al, 
2003). In addition, compared with bipolar mania, bipolar depression is associated with an 
increased risk of suicide and psy chosocial impairment ( Altshuler et al, 2002; Calabrese 
etal, 2003 , 2004; Dilsaver et al, 1997; Leverich et al, 2003; MacQueen et al, 2001 ).
Although there is a substantial burden associated with bipolar depression, the treatment 
of this phase of bipolar disorder has not been as widely  studied as the treatment of bipolar 
mania ,and pharm acotherapeutic option s are limited. At pr esent, onl y Seroquel 
(quetiapine) , Seroquel XR (quetiapine XR), Symbyax (olanzapine and fluoxetine) , and 
Latuda (lurasidone HCl) are approved b y the FDA for the treatment of patients with 
bipolar depression. Other common pharmacotherapi es include lithium, anticonvulsants 
(eg, valproate ,lamotrigine), antidepressants, at ypical antipsy chotics, or combinations of 
these.
Treatment needs are not completely  met by  the currentl y available therapies; and only  a 
low percentage of patients persist ently  benefit from them. A significant percentage of 
patients do not fully  respond to the currentl y available treatment sand continue to 
experience subthreshold sy mptoms and even relapse. Side effects commonly  associated 
with the currentl y available treatment sfor bipolar depression include tremors, 
psychomotor slowing, cognitive impairment, exacerbation of agitation, nephrotoxicity , 
altered th yroid function, and sexual dysfunction. Atypical antipsychotics in particular 
have been associated with an increase d risk of metabolic side effects, including body  
weight gain, dy slipidemia, glucose intolerance, and ty pe 2 diabetes. The use of 
antidepressants hasbeen shown to increase the risk of switching to the manic phase. 
More effective therapies with improved sid e effect profiles are still needed to enhance 
outcomes in these patients without the possibility  of inducing mania or rapid cy cling. 
Forest Laboratories, LLC Page 19 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
Dysfunction in dopamine ( DA) neurotransmission has been implicated in the 
pathophy siology  of bipolar disorder. Several line s of evidence suggest that the manic 
phase is associated with increased DA neurotransmission and the depressive phase with 
decreased DA neurotransmission. I t has been h ypothesized that the cyclical nature of 
bipolar disorder is due to alterations between t hese hy per-and hypodopaminergic states
(Berk et al, 2007 ). The contribution sof individual D 2-like receptor subt ypes (D 2, D3, D4) 
to bipolar disorder arenot fully  established . However, there is increasing evidence that 
D3receptors may  play  an important role in depression. Evidence for this has been derived 
mainly  from studies in mice with a targeted disruption of D 3receptors (D 3(-/-) mice). 
These animals are more resistant to stressful procedures , display  anxioly tic-likebehavior ,
and are more sensitive to antidepressants in behavioral models compared with the 
wild-type littermates ( Leggio et al, 2008 ; Steiner et al, 1997). A compound with a 
“DA system stabilizing” effect and with preferable D 3receptor functional antagon ist 
properties may  prove to be most beneficial for the treatment of all the phases of bipolar 
disorder including bipolar depression. RGH -188 (cariprazine) exhibits these 
characteristics.
Cariprazine is an orall y active and potent dopamine D 3-preferring D 3/D2receptor partial 
agonist discovered b y Gedeon Richter Plc ., Budapest, Hungary , and currently  in 
development b y Forest Laboratories, LLC (an Allergan Affiliate ),and Gedeon Richter 
Plc,for the treatment of schizophrenia , acute bipolar mania , bipolar depression, and as 
adjunctive treatment for major depressive disorder . In September 2015, cariprazine 
(VRAYLAR™) was approved in the United States for the treatment of schizophrenia, at 
doses of 1.5 to 6 mg/day , and for the acute treatment of manic or mixed e pisodes 
associated with bipolar I disorder, at doses of 3 to 6 mg/day . 
The chemical name of the hy drochloride salt of cariprazine is trans -N-{4- [2-[4-
(2,3-dichlorophen yl)-piperazine-1- yl]-ethyl]-cyclohexy l}-N’,N’ -dimethy lurea
hydrochloride. Its molecular formula is C 21H32Cl2N4O HCl; its molecular weight is 
463.87. Two main metabolites, desmethy l and didesmethy l cariprazine, have been 
identified. The receptor binding profile of both these metabolites is similar to that of the 
parent compound .
A unique feature of cariprazine is that it binds with significantl y higher affinity  to D 3than 
to D2receptors. Its affinity for D 3receptors is approximately  1 order of magnitude greater 
than that for D 2receptors . Similar to aripiprazole, but unlike other aty pical 
antipsy chotics, cariprazine acts as a “DA system stabilizer.” Cariprazine display s partial 
agonist as well as antagonist activity  on bios ynthesis -(and release -) modulating 
presynaptic D 2receptors and has preferential dopaminerg ic actions in the limbic regions. 
However, cariprazine is more potent than aripiprazole, and the degree of its apparent 
partial agonist activity  is greater. 
Forest Laboratories, LLC Page 20 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
Cariprazine also has considerable affinity  for, and is a partial agonist and antagonist at, 
the ser otonin 5 -HT 1Aand 5 -HT 2Breceptors, respectively . Antidepressant- likeand/or 
anxioly tic-like effects of cariprazine may  also be mediated through these receptors. 
Cariprazine has low potency at other receptor sites, such as the 5 -HT 2C, histamine H 1, and 
adrenergic receptor sites.
Cariprazine was evaluated in patients with bipolar depression in 2 multicenter, 
randomized, double -blind, placebo -controlled studies ( Study  RGH -MD-52[2011] and 
Study  RGH -MD-56[2014] ). 
Study  RGH -MD-52 was 11 weeks in duration: a n o-drug washout period of up to 1 week, 
8 weeks of double -blind treatment, and 2 weeks of safet y follow- up with treatment as 
determined b y the PI. This was a fixed- flexible dose study . A total of 227 Bipolar I and II
patients were randomized to 1 of 3 treatment groups and received at least 1 dose of the 
investigational product: placebo (n = 77), cariprazine low dose (0.25- 0.75 mg/day , 
n =75) and cariprazine high dose (1.5 -3.0 mg/day, n = 75). The dose was fixed for first 
4weeks of double -blind treatment; all patients received the lower of the dose range 
(1capsule; placebo, cariprazine 0.25 mg/day , or cariprazine 1.5 mg/day ). At the end of 
Week 4, the dose could be increased to 2 capsules if r esponse was not adequate 
(<40% reduction in Montgomery -Åsbe rgDepression Rating Scale [MADRS] score from 
baseline) and there were no significant tolerability issues as judged b y the Investigator. 
Approximately  76% of the patients completed the study : 78% in the placebo group, 
84% in the cariprazine low- dose group, and 65% in the cariprazine high -dose group. 
More patients discontinued for adverse events (AEs) in the cariprazine high -dose group 
(9.3%) than in the placebo group (2.6%) and cariprazine low -dose group (4.0%). The 
average patient age was 39 years, and approximately  64% were female. The 3 treatment 
groups were balanced with respect to demographics and baseline characteristics. For the 
primary  efficacy  parameter, the change from baseline to the end of Week 8 in the 
MADRS total score using mixed- effects model for repeated measures (MMRM), the 
overall p- value was not statistically  significant. Numerical improvement was seen in the 
cariprazine high -dose group relative to the placebo group up to end of week 6. Similar 
results were seen for other efficacy  paramete rs. SAEs were reported in 6patients 
(2patient s in the placebo group, 2patients in the ca riprazine low -dose group, and 
2patients in the cariprazine high -dose group). Treatment -emergent adverse events 
(TEAEs) reported in at least 10% of patients in any t reatment group included insomnia, 
akathisia, headache, dry  mouth, nausea, upper respiratory  tract infection and diarrhea. Of 
these, insomnia, akathisia, dry  mouth, nausea and diarrhea were reported more frequently  
in the cariprazine -treated patients. 
Forest Laboratories, LLC Page 21 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
Study RGH -MD-56was 11 weeks in duration and comprised up to 14 day s of screening 
followed by 8 weeks of double -blind treatment and 1 week of safet y follow -up. A total of 
584bipolar I patients were randomized to 1 of 4 treatment groups and 578 patients 
received at least 1 dose of the investigational product : placebo (n = 145), cariprazine 
0.75 mg/day  (n=141), cariprazine 1.5 mg/day  (n = 146), cariprazine 3 mg/day  (n = 146). 
Overall, 72.5% of the patients completed the study: 72.4% in the placebo group, 73.0% in 
the cariprazine 0.75 mg/day  group, 80.1% in the cariprazine 1.5 mg/day  group, and 
64.4% in the cariprazine 3 mg/day  group. The average patient age was 42 years, and 
approximately  62% were female. For both the primary  and secondary  efficacy  
parameters, c hange from baseline in MADRS total score and Clinical Global 
Impressions -Severit y (CGI-S)score at Week 6, statistically  significant improvement was 
demonstrated for the cariprazine 1.5 mg dose relative to placebo. Nominally  significant 
improvement was shown for cariprazine 3 mg, which did not remain statistically  
significant after adjusting for multiplicity . No statistically  significant treatment effect was 
shown for the 0.75 mg dose at Week 6. A post -hoc anal ysis of patients who completed 
the full 8 we eks of treatment (completer population) in Study  RGH -MD-56 demonstrated 
similar reductions from baseline relative to placebo in MADRS total score for the 
cariprazine 1.5 and 3 mg/day  groups at Week 6 and Week 8.Cariprazi ne was generally  
well-tolerated. Nodeaths were reported during the study . Serious adverse events were 
reported for 5 patients (3.4%) in the placebo group, 1 patient (0.7%) in the cariprazine 
0.75 mg group, and 2 patients (1. 4%) each in the cariprazine 1.5 mg and 3 mg treatment 
groups. Adve rse events that led to discontinuation were reported in similar proportions of 
patients across the placebo (10.3%) and cariprazine (8.2% -11.6%) treatment groups. The 
most common AEs that led to discontinuation were akathisia, agitation, anxiety , and 
depres sion. Overall, TEAEs were reported for 55% of patients in the placebo treatment 
group and 57%- 62% of patients in the cariprazine treatment groups. Akathisia and 
irritability  were the onl y TEAEs reported for ≥ 5% of patients in any  cariprazine 
treatment group and at an incidence at least twice that of the placebo group. 
Based upon these data , the current study  is designed to prospectivel y confirm the efficacy  
of a fixed- dose regimen of cariprazine 1.5 mg /day or 3 mg /day compared to placebo for 
treatment of the depressive episode in patients with bipolar I disorder . The safet y and 
tolerabi lity of the fixed -dose regimens will be evaluated . 
A description of the chemistry , pharmacology , toxicology , pharmacokinetics, and clinical 
results of cariprazine is provid ed in the Investigator’s Brochure ( RGH -188 [cariprazine] , 
2015). 
Forest Laboratories, LLC Page 22 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
8.0 STUDY OBJECTIVES
The objective of this study  isto evaluate the efficacy , safety , and tolerability of 
cariprazine 1.5 mg/day  and 3.0 mg/day  relative to placebo in patient s with bipolar I 
depression. 
Forest Laboratories, LLC Page 23 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
9.0 INVESTIGATIONAL PLAN
9.1 OVERALL STUDY DESIGN AND PLAN: DESCRIPTIO N
This clinical study  will be a multicenter, randomized, double -blind, placebo -controlled, 
parallel -group ,fixed -dose study  in adult patients with a Diagnostic and Statistical 
Manual of Mental Disorders , Fifth Edition (DSM -5; American Ps ychiatric Association, 
2013) diagnosis of B ipolar I disorder who are currently  experiencing a major depressive 
episode.
The study  will be conducted in outpatients (i.e., non -hospitalized) and will con sist of 
approximately  7 to 14 day s of screening and washout f ollowed by  6weeks of 
double -blind treatment and a 1-week safet y follow- up period. At the end of the screening
period, patient s meeting the eligibility criteria for this study  will be randomized (1:1:1 ) to 
1 of 3 treatment groups ( placebo, cariprazine 1.5mg/day , cariprazine 3 mg/day ). The 
study  is designed to enroll outpatients, but as per local clinical practice, patients may  be 
hospitalized for up to 7 day s during the screening period or during the first week of 
treatment with double -blind investigational product. Further need for hospitalization will 
require consultation with the Study  Physician. A total of 480 patients are planned to be 
randomized in this study .
Patients who complete 6 weeks of double -blind treatment or who prematurely  
discontinue before completing 6 weeks of double -blind treatment will be followed for 
1more week (safet y follow- up period). During the safet y follow -up period, patient s may  
be started on a standard treatment as determined by the PI. No investigational product 
will be administered during the safet y follow- up period.
  
Forest Laboratories, LLC Page 24 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

9.2 DISCUSSION OF STUDY DESIGN, INCLUDING TH E CHOICE 
OF CONTROL GROUPS
The double -blind design was adopted to minimize sy stematic bias resulting from the 
Investigator or the patient knowing the treatment being administered. Randomization is 
expected to minimize patient selection bias and increase baseline comparability  among 
the treatment groups. The doses of cariprazine under study  were chosen on the basis of 
experience from the RGH -MD-52 and RGH -MD-56 studies (see Section 7.0), as well as 
experience in the cariprazine development program in healthy  volunteers and patients 
with other indications and other at ypical antips ychotics for the treatment of bipolar 
depress ion. The use of a placebo control is critical to the study  to allow discrimination of 
patient outcomes caused by  the individual dose levels of cariprazine from outcomes 
caused b y other factors (e.g., the observer or patient expectations, the natural progre ssion 
of the disease, the conditions of being in a study ).
No double- blind down-taper has been included as cessation of cariprazine at doses 
comparable to those under study  has not given rise to appreciable discontinuation 
symptoms. 
Forest Laboratories, LLC Page 25 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

9.3 SELECTION OF STUDY P OPU LATION
9.3.1 Inclusion Criteria
Tobe eligible to participate in the study , patients must meet the following criteria:
Inclusion criteria to be assessed at Visit 1 (Screening)
1.Written informed consent , signed, obtained from the patient before the initiation of 
any study -specific procedures
2.Male or female patients 1 8 to 65 y ears of age, inclusive
3.Currently  meet the DSM -5criteria for bipolar I disorder without psychotic features 
confirmed b y the administration of the Mini I nternational Ne urops ychiatric Interview 
(MIN I), with a current major depressive episode of at least 4 weeks and not 
exceeding 12 months in duration 
4.Currently  treated as a n outpatient at the time of enrollment 
5. A verified previous manic or mixed episode. Verification must include one of the 
following sources:
a.Treatment of mania with an anti -manic agent (eg, lithium or 
divalproate) or antipsy chotic medication with an approved 
indication for mania
b.Hospital records /Medical records
c.Patient report corroborated by  caretaker or previous or current 
treating clinician 
6. 17- item Hamilt on Depression Rating Scale (HAM D-17) total score ≥ 20
7.HAMD- 17 item 1 score ≥ 2
8.CGI-Sscore ≥ 4
9.Negative serum β- human chorionic gonadotropin (β -hCG) pregnancy  test (women of 
childbearing potential only )
10.Normal ph ysical examination, clinical laboratory  test results, and electrocardiogram 
(ECG) results or abnormal findings that are judged not clinically  significant by  the PI  
Forest Laboratories, LLC Page 26 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
Inclusion criteria to be assessed at Visit 2 (Baseline)
11.Continue to meet Visit 1 inclusion criteria
9.3.2 Exclusion Criteria
Patient s who meet an y of the following criteria will not be eligible to participate in the 
study :
Exclusion criteria to be assessed at Visit 1 (Screening)
Psychiatric Criteria
1. Young Mania Rating Scale (YMRS) total score > 12
2.Four or more episodes of a mood disturbance (depression, mania, hy pomania, or 
mixed state) within the 12 months before Vis it 1
3.Any current axis 1 psy chiatric diagnosis other than bipolar disorder with the 
exception of specific phobias 
4.History  of meeting DSM -5criteria for:
○ Dementia, amnesic, or other cognitive disorder
○Schizophrenia, schizoaffective, or other psy chotic disorder
○Mental retardation
5.DSM -5–based diagnosis of borderline or antisocial personality disorder or other 
axisII disorder of sufficient severit y to interfere with participation in this study
6.History  of meeting DSM -5 criteria for substance- related disorders (excluding 
caffeine -related and tobacco -related disorders) within the 6 months before Visit 1
7.Positive result on blood alcohol test or urine drug screen for an y prohibited 
medication. Exception: 
○patients with a positive cannabinoid on entry  may  be retested before 
randomization. I f the patient remains positive, the patient is no longer eligible 
○ patients positive for opiates on entry , discussion with Study  Physician is required.
  
Forest Laboratories, LLC Page 27 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
 
 
 
 
Treatment -Related Criteria:
14.Electroconvulsive thera py in the 3 months before Visit 1
15.Previous lack of response to electroconvulsive therap y
16.Treatment with a depot antipsy chotic drug within 6 months prior to Visit 1
17.Treatment with clozapine in a dose of > 50mg/day in the past 2 y ears
 
 
 
 
 
19.Previous treatment with vagus nerve stimulation ortranscranial magnetic stimulation 
within 6 months before Visit 1 
Forest Laboratories, LLC Page 28 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

20.Prior participation with any  clinical trials, involving experimental or investigational 
drugs, within 6 months before Visit 1 or during the study
21.Initiation or termination of psy chotherapy  for depression within the 3 months 
preceding Visit 1, or plans to initiate, terminate, or change such therap y during the 
course of the stud y. 
22.Initiation or termination of phototherap y within the 2 weeks bef ore screening, or 
plans to initiate same during the course of the study
Other Medical Criteria:
23.  
 
 
24.Female patients who meet the following criteria:
oPregnant, breastfeeding, or planning to become pregnant or breastfeed during the 
study
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Forest Laboratories, LLC Page 29 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30.Gastric b ypass or an y condition that would be expected to affect drug absorption 
(lapband procedures are acceptable if there is no problem with absorption)
 
  
Forest Laboratories, LLC Page 30 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

32.Known history  of cataracts or retinal detachment
33.Known human immunodefi ciency  virus infection
 
 
 
 
Other Criteria:
38.Employ ee, or immediate relative of an employ ee, of the Sponsor , any of its affiliates 
or partners, or the stud y center
 
 
 
  
Forest Laboratories, LLC Page 31 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

9.3.3 Removal of Patient s from Therapy or Assessment
A premature discontinuation will occur when a patient who signed the ICFceases 
participation in the study , regardless of circumstances, before the completion of the 
protocol . Patient s can be prematurel y disco ntinued from the study  for one of the 
following reasons:
Screen Failure ( Failure to meet inclusion/exclusion criteria)
Withdrawal of consent
Adverse event
Lack of Efficacy
Protocol violation
Non-compliance with Study  Drug
Lost to follow -up
Study terminated b y Sponsor
Site terminated by  Sponsor
Other
A patient completing Visits 1 through 6 will be considered a completer. All randomized
patient s who prematurely discontinue from the study ,regardless of the cause ,should be
seen for a final assessment at an early termination (ET) visit. A final assessment will be 
defined as completion of the evaluations scheduled for Visit 6/ET ). All investigational 
products dispensed at earlier visits thathad not been previousl y collected should be 
collecte d at the final visit . Patients refusing to come in for a final visit must be requested 
in writing, with a registered letter, to come in for an ET visit and to return any  unused 
investigational product. A cop y of the letter, together with the source documentation, will 
be kept b y the Investigator. The reasons for premature discontinuation from the study will 
be reflected on the stud y termination record of the eCRF .
Patients with Visit 6 /ET more than 4 days after the last dose of double -blind 
investiga tional product will be administered safety assessments only.
9.3.4 Patient Replacement Procedures
Patient s in this study  who prematurel y discontinue treatment will not be replaced. 
Forest Laboratories, LLC Page 32 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
9.4 TREATMENTS
9.4.1 Treatments Administered
Investigational product in the form of capsule s packaged in blister packs will be provided 
bythe S ponsor . No investigational product will be administered during the screening 
period or the safet y follow -up period. For the 6-week double -blind treatment period, 
patients will be supplied with identicall y appearing capsules of either cariprazine or 
placebo.
9.4.2 Identity of Investigational Product(s)
Investigational product will be supplied in blister packs containing 10capsules and will 
be labeled with the protocol number, the visit numbe r/space to write visit numbe r, storage 
information, warning language (viz, “Caution: New Drug —Limited by Federal Law to 
Investigational Use”), and instructions to take the capsules once dail y as directed, and the 
medication identification number. Investigational product labels will be country  specific . 
Immediately  before dispensing the investigational product , the Investigator will write the 
patient ’s initials, site number, and date on the label .
All investigational products will be provided b y the Sponsor ,or designees, to the study  
centers. Investigational product must be stored in an appropriate secure area ( e.g., a 
locked cabinet in a locked room) at controlled room temperature  
with excursions permitted between )and must be 
protected from light, heat ,and moisture.
The Investigator is responsible for recording the receipt and use of all investigational 
products supplied and for ensuring the supervision of the storage and allocation of these 
supplies . All un used investigational products must be returned ;and,whenever 
investigational products are returned ,unit counts must be performed . All investigational 
products must be accounted for .At the end of the study , or upon drug expiration, any  
unused investigational product must be returned to the Sponsor or Sponsor's designee.
9.4.3 Method of Assigning Patient s to Treatment Groups
 
 
 
  
Forest Laboratories, LLC Page 33 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

Each stud y center will be provided with investigational products. An interactive 
voice/intera ctive Web response sy stem (I xRS) will be used during the stud y to monitor 
enrollme nt and medication allocation. If the patient meets the randomization criteria, the 
study  center will contac t the I xRS at end of Visit 2 to randomize the patient. IxRSwill 
randomize the patient to the appropriate treatmen t arm (placebo, cariprazine 1.5 mg/day, 
or cariprazine 3.0 mg/day ) and determine the investigational product number to be 
assigned to the patient based on the randomization.
9.4.4 Selection of Dos ages in the Study
The doses of cariprazine selected for this study  were based on the results from 
2completed studies in patients with bipolar depression ( RGH -MD-52 and RGH -MD-56), 
as well as experience in the cariprazine development program in healthy  volunteers and 
patients with other indications and other at ypical antipsychotics for the treatment of
bipolar depression .Study RGH -MD-52 indicated numericall y better results for the 
high-dose cariprazine group (1.5- 3.0 mg/day ) relative to placebo up to end of Week 6. In 
the cariprazine low-dose group (0.25- 0.75 mg/day), better efficacy  was observed 
following a dose increase, and tolerability  was not compromised. Thus, cariprazine 0.75, 
1.5, and 3.0 mg/day  were selected for further evaluation in Study  RGH -MD-56.
In Stud y RGH -MD-56, for both the primary  and secondary  efficacy  parameters, change 
from baseli ne in MADRS total score and CGI -S score at Week 6, statistically  significant 
improvement was demonstrated for the cariprazine 1.5 mg dose relative to placebo. 
Nominally  significant improvement was shown for cariprazine 3 mg, which did not 
remain statistically  significant after adjusting for multiplicity . No statistically  significant 
treatment effect was shown for the 0.75 mg dose at Week 6. A post -hoc analy sis of 
patients who completed the full 8 weeks of treatment (completer population) in 
Study RGH -MD-56 d emonstrated similar reductions from baseline relative to placebo in 
MADRS total score for the cariprazine 1.5 and 3 mg/day  groups at Week 6 and Week 8.
The primary  efficacy  results and the post -hoc completers anal ysis in Study  RGH -MD-56 
led to the selectio n of the cariprazine 1.5 and 3 mg/day  doses for further evaluation in this 
study . A dose higher than 3 mg/day  was not chosen because of concerns related to the 
potential for higher extrapy ramidal sy mptom rates with increasing cariprazine dose.
A fixed -dose regimen allow sfor unambiguous evaluation of safet y and efficacy  of 
individual doses . 
Forest Laboratories, LLC Page 34 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
9.4.5 Selection and Timing of Dose for Each Patient
All investigational products will be dispensed in blister packs. Each blister pack will 
contain 10 capsules arranged in 10 columns and 1 row, adequate for the 7 day s of the 
week plus 3 extra day s. The configuration of the blister packs is provided in 
Table 9.4.5–1.
At Visit 2, patients w ho continue to meet all eligibility  criteria will be assigned a 
randomization number and dispensed a corresponding blister pack of double -blind 
investigational product for the first week of double -blind treatment. Patients will be 
instructed to take 1 caps ule daily , in order from left to right of the blister pack ,beginning 
on the evening of Visit 2 or the morning after Visit 2
At Visit 3 (end of week 1 of double -blind treatment ) patients will be dispensed 1 blister 
pack . At Visits 4 and 5 (end of week 2 and end of week 4 of double -blind treatment), 
patients will be dispensed 2 blister packs.
All patients randomized to cariprazine dose groups will receive cariprazine 1.5 mg/day  
for 2 weeks, from Day  1through Day 14. For patients randomized to the cariprazine 
3.0mg/day  group, the dose will be increased to 3.0 mg/day  on Day  15. 
Drug holiday s (up to a maximum of 3 consecutive day s) are allowed if there are 
tolerability  problems at the discretion of the Investigator . Patients unable to tolerate the 
fixed dose of the investigational product or patients off drug for 4 or more consecutive 
days will be prematurely  discontinued from the study .
All investigational products will be taken orall y as a single daily dose at app roximately  
the same time of day  (morning or evening). The dosing time can be switched if there are 
tolerability  problems. Any  switch must allow at least 24 hours between 2 consecutive 
doses and must be documented in the eCRF.
At each visit, patients will be instructed to return all unused investigational product. 
Forest Laboratories, LLC Page 35 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
Table 9.4.5 –1. Blister Card Configuration and Dosing Regimen
Visit 2
Days 1 -7 
+ 3extra daysVisit 3
Days 8 -14 
+ 3extra daysVisit 4 
Days 15 -28
+ 6extra daysVisit 5
Days 29 -42
+ 6extra days
Treatment group: placebo
Row1 0 mg 0 mg 0 mg 0 mg
Treatment group: cariprazine 1.5 mg/day
Row1 1.5 mg 1.5 mg 1.5 mg 1.5 mg
Treatment group: cariprazine 3.0 mg/day
Row1 1.5 mg 1.5 mg 3.0mg 3.0 mg
Note: At Visit 2 and Visit 3 patients will be dis pensed 1 blister pack. At Visit 4 and Visit 5, patients will be dispensed 
2blister packs. Each blister pack will contain 10 capsules, adequate for 7 days plus 3 extra days.
9.4.6 Blind ing
The study  will be conducted as a double -blind investigation. A list of patient 
randomization codes will be generated b y the Sponsor’s Statistical Programming ,and 
implemented by  the IxRSvendor (an electronic version wil l be stored on a secure server) . 
This list will identify  each patient by  randomization number and include the patient’s 
corresponding treatment assignment. 
9.4.7 Unblinding
Any unblinding at the study  center level should be done only  in an emergency  that 
requires for the investigation al product to be identified for the medical management of 
the patient . The Investigator has to notify  the study  physician immediatel y 
(see Appendix II) and a full written explanation must be provided if the blind is broken. 
Before the investigational product is unblinded, every  attempt should be made to discuss 
the case with the Stud y Physician . Breaking the code at the study  center will immediately  
disqualify  the patient from further participation in the study .
Treatment codes may  be broken b y the Sponsor’s Global Drug Safet ydepartment , for 
regulatory  reporting purposes. In such cases, the study  staff will be kept blinded and the 
patient will not need to be disqualified from the study .
In an emergency , the Investigator can obtain the treatment assignm ent of any  patient at 
his or her study  site through the I xRS. In an emergency , the Investigator will access the 
IxRSto break the blind.
The unblinding of bioanaly tical representatives is to be carried out in a secure manner 
following the Sponsor’s standa rd operating procedures. Extreme care and diligence will 
be taken to ensure no other individuals outside the bioanaly tical team will be unblinded. 
Forest Laboratories, LLC Page 36 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
9.4.8 Prior and Concomitant Therapy
A complete list of drugs that are allowed and not allowed as concomitant medica tions for 
either episodic or long -term use is provided in Appendix I II. Throughout the duration of 
this study , additional psychotropic medications, including ps ychostimulants, are not 
allowed, with some notable exceptions listed below. Psy chotropic medications include 
the following: antips ychotics, antidepressants (including monoamine oxidase -B 
inhibitors), stimulants, anticonvulsants/mood stabilizers, sedatives/hy pnotics/anxioly tics, 
dopamine releasing drugs or dopamine agonists, and psy chotropic drugs not otherwise 
specified (including herbal products ).
Patients will be asked to abstain from drinking alcohol during the stud y. Patients who 
have been taking stable doses of benzodiazepines (up to 2 mg/day ) for at least 1 month 
before randomization can continue use. Medi cally  appropriate episodic use ( up to 3 day s)
of narcotic analgesics for acute medical indications (i.e., tooth extraction) is allowed 
during the stud y.
Medication history , including the use of ps ychotropic medication and of any other 
medication, will be recorded at Visit 1 (Screening). Thereafter, an y changes in 
concomitant medications or new medications added will be recorded in the eCRF.
For insomnia the following will be allowed. It should not be prescribed 
prophylactically .
Zolpidem ( maximum of 10 mg/day )
Zolpidem extended release (maximum of 12.5 mg/day )
Zaleplon (maximum of 20 mg/day )
Eszopiclone (maximum of 3 mg/day )
Zopiclone (maximum of 7.5 mg/day )
Chloral hy drate (maximum of 1000 mg/day ) may  be used acutely  with approval from 
Study Physician )
These medications must be administered before bedtime as recommended in their 
prescribing information. The medication must be documented on the concomitant 
medications page of the eCRF. No such medication is permitted within 8 hours of 
psychiatric or neurological assessments. 
Forest Laboratories, LLC Page 37 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
For EPSs or akathisia :
For EPSs or akathisia that emerge or worsen during the stud y, the following rescue 
medications will be allowed; however, each of the 3 EPS scales (Abnormal I nvoluntary  
Movement Scale [AIMS], Barnes Akathisia Rating Scale [BARS], and Simpson Angus 
Scale [SAS]) should first be performed (unless a medical urgency  [eg, d ystonia, severe 
akathisia, etc] requires otherwise) to support the decision to administer the medications:
Benztropine (up to 4 mg/day  orall y or up to 2 mg/day if given parenterally) or 
equivalent (eg, trihex yphenidyl up to 6 mg/day  in divided doses)
Diphenhy dramine (up to 50 mg/day )for EPS
Propranolol for the treatment of akathisia. Dail y dose of propranolol depends on heart 
rate and BP (up to 160 mg/day )
The medication listed above should not be used prophy lacticall y. The need for continued 
use of these medications should be regularl y assessed by  the PI  and documented 
appropriatel y. The EPSs must be documented on the AE page of the eCRF, and the 
medication on the concomitant medications page of the eCRF.
Injectable age nts are not allowed, except for the treatment of an acute dy stonic reaction if 
deemed necessary .
Rescue medications for agitation, restlessness, and hostility:
Episodic use of lorazepam up to 2 mg/day  (or equivalent) and for up to 3 consecutive 
days at a t ime is allowed for agitation, restlessness, and hostility .
The agitation, restlessness, or hostility  must be documented on the AE and/or the medical 
history  page of the eCRF. The medication use must be documented on the rescue 
medication page of the eCRF. Efficacy  assessments s hould not be performed within 
8hours of administration of lorazepam or equivalent benzodiazepine or within 24 hours 
of administration of diazepam.
9.4.9 Monitoring Treatment Compliance
Investigational product compliance will be monitored b y counting the number of capsules 
dispensed and the number returned b y the patient. Before new investigational product is 
dispensed at an y visit, every  effort will be made to collect all unused investigational 
product. If a patient demonstrates poor compli ance at an y time during the study  (< 80% 
or > 120% measured b y pill counts), then they  should be discontinued from the study . 
Forest Laboratories, LLC Page 38 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
9.5 EFFICACY AND SAFETY VARIABLES
9.5.1 Diagnostic and Efficacy Assessment s
9.5.1.1 Diagnostic Assessment
Mini International Neuropsychiatric Interview (Version 7.0.0, 01 Jan 2014)
The MINI(Version 7.0.0, 01 Jan 201 4)is a clinician -rated diagnostic assessment that will 
be considered a source document in this study . The interview will be administered by  the 
PI or Sub- Investigator who is a psy chiatrist or a doctoral -level clinical ps ychologist or 
who has extensive professional training and experience in the diagnosis of mental illness .
9.5.1.2 Primary Efficacy Assessment
Montgomery -Åsberg Depression Rating Scale
The MADRS (Montgomery  and Åsberg, 1979) i s a 10 -item, clinician- rated scale that 
evaluates the patient’s depressive s ymptomatology  during the past week. Patients are 
rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, 
suicidality , reduced sleep or appetite, difficulty  in concentration, and lack of interest. 
Each item will be scored on a 7- point scale with a score of 0 reflecting no symptoms and 
a score of 6 reflecting symptoms of maximum severity. This scale will be administered 
by a trained rater with adequate experience in the assessment of the patient’s depressive 
symptomatology  using the MADRS.
9.5.1.3 Secondary Efficacy Assessment
Clinical Global Impressions–Severity
The CGI -S (Gu y, 1976) is a clinician -rated scale that measures the overall severit y of a 
patient’s illnes s in comparison with the severit y of other patients the ph ysician has 
observed. The patient is rated on a scale from 1 to 7 with 1 indicating a “normal state” 
and 7 indicating “among the most extremely ill patients.” The CGI -S will be administered 
by the P I or a Sub -Investigator with extensive professional training and experience in 
assessing mental illness. 
Forest Laboratories, LLC Page 39 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
9 4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.5.2.1 Adverse Events
An AE is a ny untoward medical occurren ce in a patient or clinical investigation patient
administered a pharmaceutical product and which does not necessarily  have to have a 
causal relationship with thistreatment .An AE can therefore be any  unfavorable and 
unintended sign (including an abnormal laboratory finding, for example), symptom, or 
disease temporall y associated with the use of a medicinal product, whether or not 
considered related to the medicinal product (ICH -E2A) . 
Forest Laboratories, LLC Page 40 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

For the purpose of the site’s data collection responsibilities, any  untoward event that was 
reported from the time the patient signed the ICF until 30 day s after the final 
protocol -defined stud y visit or, if the final visit does not occur, the last known dose of 
investigational p roduct , is to be considered an AE.
Examples of AEsare as follows :
Changes in the general condition of the patient
Subjecti ve sy mptoms offered by  or elicited from the patient
Objective signs observed by  the Investigator or other study  site personnel
All diseases that occur after signing inform consent , including an y change in severity 
or frequency  of preexisting disease
All clinically  relevant abnormalities in laboratory  values or clinicall y relevant 
physical findings that occur during the study schedule
Please note medical procedure sscheduled prior to consenting, but occurring during the 
study  should not be capture das AEs , but should be listed in the medical history  if related 
to a pre -existing condition .
9.5.2.2 Causality Assessment
For each AE, the Investigator must provide an assessment of causal relati onship to the 
investigational product. The causality  assessment must be recorded on the appropriate 
AEreporting page of the patient ’s eCRF. Causal relationship must be assessed by 
answering the following question:
Is there a reasonable possibility  the investigation alproduct caused the event?
Yes: There is evidence to suggest a causal relationship between the investigational 
product and AE ; i.e.:
There is a reasonable temporal relationship between the 
investigational product and the event, and /or
The even t is unlikel y to be attributed to underl ying/concurrent 
disease, other investigational product s, or other factors, and/or
Positive dechallenge and/or rechallenge exist 
Forest Laboratories, LLC Page 41 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
No: There is no evidence to suggest a causal relationship between the 
investigational product and AE, i.e.:
There is no reasonable temporal relationship between the 
investigational product and the event, or
The patient did not take the investigational product, or
The event is likel y to be attributed to underl ying/concurrent 
disease, other investigational product s, or other factors, or
The event is commonl y occurring in the (stud y) population 
independent of investigational product exposure
9.5.2.3 Severity Assessment
The Investigator will provide an assessment of the severit y of each AEby recording a 
severit y rating on the appropriate AE reporting page of the patient ’s eCRF . Severity,
which is a description of the intensity  of manifestation of the AE, is distinct from 
seriousness, which implies a patient outcome or AE -required treatment measure 
associated with a threat to life or functionality (Section 9.5.2.4). Severit y will be assessed 
according to the following scale:
Mild: A type of AEthat is usually  transient and may  require only minimal 
treatment or therapeutic intervention. The event does not generally  
interfere with usual activities of daily  living.
Moder ate: A type of AEthat is usually  alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily  living, 
causing discomfort but poses no significant or permanent risk of harm to 
the research participant.
Severe: A type of AEthat interrupts usual activities of daily  living, or significantl y 
affects clinical status, or may require intensive therapeutic intervention.
9.5.2.4 Serious Adverse Events
An SAE is any  untoward medical occurrence that at any  dose:
Results in death
Is life threatening
Requires i npatient hospitalization or prolongati on of existing hospitalization 
Forest Laboratories, LLC Page 42 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
Results in persistent or significant disability /incapa city, or
Is a c ongenital anomal y/birth defect
Important medical events that may  not result in death, be life threatening, or require 
hospitalization may  be considered serious when, based on appropriate medical judgment, 
they may  jeopardize the patient or subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition . Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency  room or at home, blood dy scrasias or convulsions that do not result in patient
hospitalization, orthe development of investigat ional product dependency  or drug abuse.
Emergency  room visits that do not result in hospitalization should be evaluated for one of 
the other serious outcomes to determine whether they  qualify  as SAEs.
Preplanned hospitalizations ( e.g., elective procedures for pre existing conditions that did 
not worsen , such as cosmetic surgery  and hy sterectomy ) or routine (i.e. required) 
country -specific hospitalization during washout are excluded from SAE reporting.
9.5.2.5 Reporting Adverse Events and Serious Adverse Events
At each visit, patient s are to be queried regarding any  AEs or SAEs that have occurred 
since the previous visit. Patient s will be asked to volunteer information with a nonleading 
question such as, “How do y ou feel since your last visit ?” Study  site personn el will 
record all pertinent information in the patient ’s eCRF . 
All AEs must be recorded on the appropriate AE reporting page of the patient’s eCRF
whether or not they  are considered causally  related to the investigational product.
For every  AE, the Investigator must:
Provide an assessment of the seriousness of the event ( i.e., is it an SAE ?), as well as 
the severit y and casual relationship
Document all actions taken with regard to the investigational product
Detail an y other treatment measures taken for the AE
Document the outcome of the AE 
Forest Laboratories, LLC Page 43 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
In addition, patients are to be reminded, as described in the I CF and in accordance with 
Section 9.5.2.1, to notify  site personnel of an y AEs occurring during the 30 day  
post-study  period. An y AEs reported b y the patient (or patient representative) during this 
period are to be recorded in origina l source documents. AEs are also to be recorded in the 
eCRF if at least one of the following condition sismet: 1) the event meets the criteria for 
an SAE (see Sections 9.5.2.4 and 9.5.2.6), and/or 2) the event is judged b y the 
Investigator to be potentially  causall y related to investigational product.
Any AEs that are ongoing at the time of the final protocol -defined stud y visit will be 
followed until the condition returns to prestud y status, has resolved or stabilized, or can 
be explained as being unrelated to the investigational product. If a follow -up visit is 
deemed necess ary for appropriate safet y surveillance, it will take place within 30 days of 
the final protocol -defined study  visit.
9.5.2.6 Immediate Reporting of Serious Adverse Events and Events of 
Special Interest
The Sponsor is required to inform worldwide regulatory  author ities of SAE s and Ocular 
Events of Special Interest that meet specific criteria. Therefore, the Sponsor must be 
notified immediately  regarding any  SAE and Ocular Events of Special Interest that occur 
after informed consent is obtained.
Thefollowing serious and non-serious adverse events (ie, Ocular Events of Special 
Interest ) require a 15- day alert report: 
cataract, lens, or lenticular abnormality  or change, opacity , opacification or 
opalescence
blindness, night blindness, visual acuity  orvision decrease, abnormality  or change ,
visual acuity  test abnormality  or change
retinal, macular, or optic nerve degeneration, abnormality  or change; retinal pigment 
epithelium detachment, abnormality  or change
color vision decrease, abnormality  or chang e
Within 24 hours of learning of an y AE that meets one of the criteria for an SAE, the 
study  site personnel must report the event to the S ponsor’s Global Dru g Safety  
depa rtment on the SAE Form for Clinical Trials .
Within 24 hours of learning of any  non- serious Ocular Event of Special Interest, the 
study  site personnel must report the event on the Ocular Event Reporting Form . Serious 
Ocular Events should be reported on the SAE Form for Clinical Trials. 
Forest Laboratories, LLC Page 44 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
In addition to completing the appropriate form, t he Sponsor’s Study  Safet y Physician
may also be notified by  telephone.
If, during follow -up, any  nonserious AE worsens and eventuall y meets the criteria for an 
SAE, that AE should be recorded as a new SAE.
The s itemust transmit the SAE Form for Clinical Trials or the Ocular Event of Special 
Interest form to the SAE fax number shown below . Even if an initial report ismade by
telephone, the SAE Form for Clinical Trials or the Ocular Event of Special Interest form ,
completed with all available details ,must still be faxed within 24 hours of knowledge of 
the event at the study  site.
Supplemental information should be submitted as soon as available and may include 
laboratory  results, radiology  reports, progress notes, hospital admission and emergency  
room notes, holding and observation notes, discharge summaries, autops y reports, and 
death certificates.
The Investigator is expected to take all therapeutic measures necessary  for resolution of 
the SAE. Any medications or procedures necessary  for treatment of the SAE must be 
recorded on the appropriate pages of the patient ’s eCRF. All SAEs and Ocular Events of 
Special Interest are to be followed by  the study  staff until resolution or until the SAE or 
Ocular Event of Special Interest is deemed stable. The Sponsor may contact the study 
siteto solicit additional information or follow up on the event.
Fax the SAE Form for Clinical Trials to the S ponsor:
SAE Form fax number:
TheMedical E mergency  Phone number is provided in Regulator yBinder contact list. 
9.5.2.7 Reporting of Pregnancies Occurring During the Study
Study  site personnel must report every  pregnancy  from the time the patient signs the ICF 
until 30 day s after the last dose of investigational product. Within 24 hours of learning of 
the pregnancy , the study  sitepersonnel must report the event to the S ponsor’s Global 
Drug Safet y department on the Clinical Trial Pregnancy Form and fax it to the 
SAE/Pregnancy  fax number stated in Section 9.5.2.6 , even if no AE has occurred.
Pregnancies in female partners of male patients occurring during the ti meframe 
described above must also be reported.  
Forest Laboratories, LLC Page 45 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

The pregnancy  must be followed to term and the outcome reported by  completing a 
follow -up a Clinical Tr ial Pregnancy Form. Ifthe pregnancy  is assoc iated with an SAE 
(e.g., if the mother is hospitalized for hemorrhage), a separate SAE Form for Clinical 
Trials must be filed as described in Section 9.5.2.6 with the appropriate serious criterion 
(e.g., hospitalization) indicated in addition to the Pregnancy  Form .
9 8
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Forest Laboratories, LLC Page 46 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Forest Laboratories, LLC Page 47 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
9 0
 
 
 
 
 
 
 
 
 
 
 
 
 
9 1
 
 
 
 
 
 
  
Forest Laboratories, LLC Page 48 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

9 2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Forest Laboratories, LLC Page 49 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
 
 
 
 
 
 
 
 
 
 
  
Forest Laboratories, LLC Page 50 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

9.5.3 Investigational Product Concentration Measurements
Blood samples will be collected b y aqualified phlebotomist via venipuncture using 
lavender -top Vacutainer tubes containing potassium K2EDTA as the anticoagulant. A 
2-mL tube will be used to collect the samples for determination of the plasma 
concentrations of cariprazine and its metabolites .
Four blood samples ( 2mL each) will be collected at Visit 4 (Week 2), Visit 5 (Week 4), 
Visit 6 /ET(Week 6), and V isit 7 (Week 7). Samples may  be collected at any  time during 
the visit. The date and time of plasma sampling will be recorded in the eCRF along with 
the date and approximate time of the previous 3 doses of investigational product. Every  
effort should be made to collect PK samples for each patient. However, if for reasons of 
safet y or patient refusal, blood sampling is not possible, the PK sample can be skipped. 
All V acutainer and plasma collection tubes must be prechilled in an ice bath before use.
The clock times of al l blood draws will be recorded for each patient. All Vacutainer and 
polypropylene tubes will be labeled at the study  center with a code number that 
corresponds to the PID number , visit number, date ,and blood draw time. The central 
laboratory  will supply  thelabels with code numbers, blood Vacutainer tubes, and the 
polypropylene tubes. Other laboratory  supplies are the responsibility  of the Investigator.
Samples must be centrifuged for plasma harvesting within 30 minutes of blood draw.
For details on blood sample collection, plasma separation, storage, and shipment, see the 
instructions from the central laboratory (Central Laboratory  Manual) .
9.5.4 Health Economic and Outcomes Research Assessments
Not applicable.
9.5.5 Schedule of Assessments
The schedule of study  proce dures and assessments is tabulated by  visit in the Schedule of 
Evaluations in Section 2.0. The descriptions of the procedures to be performed at each 
visit are provided below.
9 1
 
 
  
Forest Laboratories, LLC Page 51 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
 
 
 
 
 
 
 
 
 
 
 
  
Forest Laboratories, LLC Page 52 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

9 2
 
 
 
 
 
 
9 3
  
Forest Laboratories, LLC Page 53 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
9 4
 
 
 
 
 
 
  
Forest Laboratories, LLC Page 54 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2


 
9 5
 
 
 
 
 
  
Forest Laboratories, LLC Page 55 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

9.6 DATA QUALITY ASSURANCE
9.6.1 Data Monitoring
Before an y patient enters the st udy, a Sponsor representative will meet with the 
Investigator and the study  sitestaff to review the procedures to be followed during the 
study . Electronic data capture (E DC)functionality  training is provided via 
computer -based training to train Investigator sand authorized designees on recording the 
data in the eCRFs using the EDC sy stem. After the first patient is enrolled, the S ponsor
representative, a Regional Site Manager (RSM) or designee , will periodically  monitor the 
progress of the stud y by conducting on -site visits. This RSM or designee will review 
query  statuses remotely , possibly  warranting more frequent communication and/or site 
visits with the In vestigator and the stud y sitestaff. The Investigator will make available 
to the RSM or de signee source documents (written notes and electronic medical records, 
if used), signed consent forms, and all other study -related documents. The Investigator
and the study  site staff will be responsible for data entry of patient data into the eCRFs 
via th e EDC sy stem, resolving data queries generated via the EDC sy stem and providing 
missing or corrected data. The Investigator or designee will be responsible for approving 
all changes performed on the data, and endorsing the patient data within the EDC sy stem. 
This approval method will include apply ing an electronic signature linked to a uniquely  
assigned username and password that together will represent a traditional handwritten 
signature used in the past.
9.6.2 Data Recording and Documentation
Data collection wi ll involve the use of the Sponsor’s EDC sy stem, to which only  
authorized personnel will have access. Patient ’sdata are to be entered into the EDC 
system by  the Investigator or designee using their assigned EDC user account. After data 
entry  into the EDC sy stem by  the Investigator or designee, a combination of manual and 
programmatic edit checks will be used to review the data for completeness, logic, and 
adherence to stud y protocol. As a result of these edits checks, data mo nitoring and
reviews ;queries may  be electronically  issued to the site and should be answered 
electronically  via the EDC sy stem.
Each query  will carry  identify ing information (assigned username, date and time) to 
assist the S ponsor and the Investigator on the origin of the data clarification request and 
the response provided b y the Investigator . All data changes made to the patient’s data via 
a data query  will be approved by  the Investigator prior to final database lock.
After all data have been reviewed an d all issues have been resolved, the database will be 
locked. 
Forest Laboratories, LLC Page 56 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
All data collected in the context of this study  will be stored and evaluated per regulatory  
requirements and applicable guidance for electronic records. Also, data will be stored and 
evaluated i n such a way  as to guarantee patient confidentiality  in accordance with the 
legal stipulations apply ing to confidentiality  of data. Study  records ( e.g., copies of 
eCRFs, laboratory  reports, patient diaries, regulatory  documents, etc.) will be retained at 
the site, along with adequate source documentation, according to FDA and ICH 
requirements. All stud y records must be available for inspection b y the S ponsor ,its 
authorized representatives, and the FDA or other health authori ties.
9.7 STATISTICAL METHODS AND DETERMINATION OF 
SAMPLE SIZE
9.7.1 Patient Populations
Four populations will be considered in the statistical anal ysis of the study .
9.7.1.1 Screened Population
The Screened Population will consist of all patient s who signed informed consent and 
received a PID number .
9.7.1.2 Randomized Population
The Randomized Population will consist of all patient s in the Screened Population who
were randomized to a treatment group in the stud y.
9.7.1.3 Safety Population
The Safet y Population will consist of all patient sin the Randomized Population who took 
at least 1 dose of double -blind investigational product.
9.7.1.4 Intent -to-Treat Population
The Intent -to-Treat (ITT) Population will consist of all patient s in the Safety  Population 
who had at least 1postbaseline assessment of MADRS total score .
9.7.2 Patient Disposition
The number and percentage of patients in 3 of the study  populations (Randomized, 
Safety, and ITT) will be summarized by  treatment group and study  center; the Screened 
Population will be summarized overall onl y by study center. 
Forest Laboratories, LLC Page 57 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
Screen -failure p atients (ie, patients screened but not randomized) and the associated 
reasons for failure to randomize will be tabulated overall for the Screened Population. 
The number and percentage of patients who completed the double- blind treatment period, 
and of pati ents who prematurel y discontinue d during the same period and who entered 
the safet y follow-up period will be presented for each treatment group and pooled across 
treatment groups for the Randomized Population. Patients are considered to have entered 
the sa fety follow- up period if they  had Visit 7 (Week 7). The reasons for premature 
discontinuation from the double- blind treatment period as recorded on the termination 
pages of the eCRFs will be summarized (number and percentage) b y treatment group for 
the Randomized Population.
9.7.3 Demographics and Other Baseline Characteristics
Demographic parameters ( e.g.,age, race, ethnicit y, sex, weight, height, BMI ) and other 
baseline characteristics will be summarized by  treatment group for the Safety and 
ITTpopulation s.
Prior medication is defined as an y medication taken before the date of the first dose of 
double -blind investigational product. Concomitant medication is defined as any  
medication taken on or after the date of the first dose of double -blind investigational 
product .
Both prior and concomitant medication use will be summarized by the number and 
proportion of patients in each treatment group receiving each medication within each 
therapeutic class for the Safety  Population. Multiple medication use by  a patient w ill only  
be counted once .
9.7.4 Extent of Exposure and Treatment Compliance
9.7.4.1 Extent of Exposure
Exposure to double -blind investigational product for the Safet y Population during the 
double -blind treatment period will be summarized for treatment duration, calculated as 
the number of day s from the date of the first dose of double -blind investigational product 
taken to the date of the last dose taken, inclusive . Descriptive statistics (n, mean, standard
deviation, minimum, median, and maximum) will be presented b y treatment group. 
Forest Laboratories, LLC Page 58 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
9.7.4.2 Measurement of Treatment Compliance
Dosing compliance for a specified period is defined as the total number of capsules 
actuall y taken b y a patient during that period divided by  the number of capsules that were 
expected to be taken during th e same period multiplied by  100. The total number of 
capsules actually taken during a specific period is calculated as the number of day s in that 
period multiplied by  the number of capsules taken each day  during that period. The 
number of capsules expected to be taken for a specific treatment period will be calculated 
by multiply ing the number of day s in that period by  the number of capsules to be taken 
per day . Descriptive statistics for investigational product compliance will be presented by  
treatment group for each period between 2 consecutive visits, as well as for the whole 
double -blind treatment period of the study  for the Safety Population.
9.7.5 Efficacy Analyses
All efficacy  analy ses will be based on the ITT Population, unless stated otherwise. The 
baseli ne for each specific efficacy  endpoint is defined as the value recorded at 
Visit 2/Week 0. I f this value is not available, the last available value before the first dose 
of double -blind investigational product will be used as the baseline value. Efficacy  results 
will be considered to be statistically  significant after co nsideration of the 
multiplicity -control strategy  for controlling the Ty pe I error at 0.05 level; details are 
described in Section 9.7.5.2 . Nominal p- values may  be computed for other efficacy  
analyses as a measure of strength of association between the endpoint and the treatment 
effect rather th an formal tests of hy potheses. All statistical hy pothesis tests will be 
performed at the 2 -sided 5% significance level for main effects. All confidence intervals 
will be 2- sided 95% confidence intervals, unless stated otherwise.
For efficacy  analy ses in which study  center is a factor, a small center will be defin ed as a 
center with fewer than 2 patients in at least 1 treatment group in the ITT Population. 
Small centers will be pooled to form pseudo-centers so that each treatment group 
includes at least 2 ITT patients within the center. Pooling will be done within each 
country  using the following algorithm: 
Based on the number of ITT patients, small centers will be ordered from the largest to the 
smallest, and centers of the same size will be ordered from the largest center number to 
the smallest center number. The pooling process starts with the largest small center from 
the top, which will be pooled with the small est from the bottom until a non -small center 
is formed. The process will be repeated using the small centers left out after the first pass. 
If any center s are left out at the end of the process, they will be pooled with the smallest 
pseudo- center. If there is more than 1 smallest pseudo -center, the pseudo- center with the 
smallest center number will be selected. In case that the pseudo center formed by  pool ing 
all small centers is still a small center, it will be pooled with the smallest non -small 
center. If there is more than 1 smallest non -small center, the one with the smallest center 
number will be selected. 
Forest Laboratories, LLC Page 59 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
These pseudo- centers will be used for all effi cacy anal yses when the model is adjusted 
for study  center.
 
 
 
 
 
9.7.5.1 Primary Efficacy Parameter s
The primary  efficacy  parameter will be the change from baseline to Week 6 in MADRS 
total score. The primary anal ysis will be performed using a MMRM with treatment 
group, stud y center, visit, and treatment group –by-visit interaction as fixed effects and 
the baseline value and baseline by -visit interaction as covariates. An unstructured 
covariance matrix will be used to model the covariance of within -patient scores. The 
Kenward -Roger approximation will be used to esti mate denominator degrees of freedom. 
The anal ysis will be performed based on all postbaseline scores using onl y the observed 
cases without imputation of missing values.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Forest Laboratories, LLC Page 60 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
.
9.7.5.2 Secondary Efficacy Parameter s
The secondary  efficacy  parameter will be change from baseline to Week 6 in CGI -S 
score. The secondary  efficacy  parameter will be analy zed using an MMRM with 
treatment group, stud y center, visit, and treatment group –by-visit interaction as fixed 
effects and the baseline CGI -S score and baseline CGI -S score –by-visit interaction as the 
covariates. An unstructured covariance matrix will be used to model the covariance of 
within -patient scores. The Kenward -Roger approximation will be used to estimate 
denominato r degrees of freedom.
To control the overall ty pe I error rate for multiple comparisons of 2 active doses versus 
placebo at Week 6 for the primary  and secondary  efficacy  parameters, the parallel 
gatekeeping procedure will be implemented (Chen et al, 2005). The 4 null hypotheses 
will be grouped into 2 families denoted by  F1 and F2, with F1 consisting of 2 null 
hypotheses for comparisons of the 2 active doses versus placebo in change from baseline 
to Week 6 in MADRS total score, and F2 consisting of 2 null h ypotheses for comparisons 
of the 2 active doses versus placebo in change from baseline to Week 6 in CGI -S score. 
Family  F1 will serve as the parallel gatekeeper for F2. The matched gatekeeping 
procedure utilizes the special logical relationship between the primary  and the secondary  
parameters to enhance the power of statistical testing. The secondary  efficacy  parameter 
will be tested at a specific dose onl y if the corresponding primary efficacy parameter is 
statistically  significant. The Simes test will be u sed to derive the local p -values for the 
interaction h ypotheses. The adjusted p -values for the 4 elementary  hypotheses will be 
calculated based on the closed testing principle. Statistical significance will be 
determined b y comparing the adjusted p -values to α = 0.050.
9 3 
Forest Laboratories, LLC Page 61 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2


 
 
 
 
 
 
 
 
 
 
 
 
  
Forest Laboratories, LLC Page 62 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Forest Laboratories, LLC Page 63 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

9 2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.
9 3
 
 
 
 
 
 
 
 
 
 
 
 
  
Forest Laboratories, LLC Page 64 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

9 4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 5
 
 
  
Forest Laboratories, LLC Page 65 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.7.6.6 Investigational Product Plasma Concentration Parameters
Plasma samples will be analy zed for the concentrations of cariprazine and its desmethy l 
and didesmethy l metabolites using a validated bioanal ytical method. A population PK 
approach will be used to estimate individual -level drug- exposure parameters 
(i.e., steady-state area -under -the-curve (AUC), stea dy-state maximum concentration 
[Cmax] , stea dy-state minimum concentration [ Cmin] ) for each of the 3 analytes. This will 
be performed via the use of appropriate nonlinear mixed -effects modeling software. The 
effec ts of demographics/covariates (eg, gender, body  weight, height, concomitant 
medications) on the pharmacokinetics of the 3 analy tes will be evaluated. The 
relationship, if an y, between effectiveness and drug -exposure parameters will be 
explored.
9.7.7 Health Econ omics and Outcomes Research Analyses
Not applicable.
9.7.8 Interim Analysis
No interim anal ysis is planned for this study . 
Forest Laboratories, LLC Page 66 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

9.7.9 Determination of Sample Size
The primary  efficacy  endpoint is the change from baseline at Week 6 in MADRS total 
score. The secondary  endpoi nt is the change from base line at Week 6 in CGI -S score. For 
the comparison of the primary  endpoint, the sample size of 160 subjects per arm will 
provide approximately  82% statistical power to show statistically  significantly  higher 
effect in each dose of cariprazine versus placebo. The study  has statistical power of 90% 
to show at least one of the two cariprazine doses is statistically  significantly  more 
efficacious than placebo in the primary  endpoint. These calculations assumed an effect 
size of 0.36 (tr eatment gro up difference relative to SD). For a given successful 
(statistically  significant) dose versus placebo with respect to the primary  endpoint, its 
probability  in detecting an effect size of 0.36 as statistically  significant versus placebo 
with respect to the secondary  endpoint is 88%. All statistical powers presented in this 
section were calculated adjusting for multiple comparisons using matched parallel 
gatekeeping procedure with the family -wise Ty pe I error rate bein g controlled at a 0.05 
level ( 2-sided). The dropout rate is assumed to be 22% at Week 6. Within -person 
correlation for both primary  and secondary  endpoints is assumed to be 0.6, as well as 
correlation between the two endpoints (pri mary  and secondary ) to be 0.6. Assumptions of 
effect si zes, correlation coefficients, and drop -out ra te are based on RGH- MD-56 study .
9.7.10 Computer Methods
Statistical analy ses will be performed using version 9.1.3 (or newer) of SAS on a 
UNIX operating s ystem.
9.8 CHANGES IN THE CONDU CT OF THE STUDY OR P LANNED 
ANALYSES
Any amendment to this protocol will be provided to the I nvestigator in writing by  the 
Sponsor . No protocol amendment may  be implemented (with the exceptions noted below) 
before it has been approved by  the IRB /IECand the signature page, signed by  the 
Investigator, has been received by  the S ponsor . If the protocol is amended to eliminate or 
reduce the risk to patients, the amendment may  be implemented before IRB/I ECreview 
and approval. However, the I RB/IECmust be informed in writing of such an amendment, 
and approval must be obtained within reasonable time limits. Deviating from the protocol 
is permitted only  if absolutely  necessary  for the safety  or clinical management of the 
patients and must immediately be reported to the Sponsor .  
Forest Laboratories, LLC Page 67 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
9.9 PROTOCOL DEVIATIONS AND VIOLATIONS
A protocol deviation is any  change, divergence, or departure from the study  design or 
procedures that is under the Investigator ’sresponsibility  and oversight (as defined by  
regulations) without prior written IRB/IEC approval or favorable opi nion of an 
appropriate amendment and that does not have a major impact on the patient ’s rights, 
safet y, or well -being, or on the integrit y and authenticity  of the stud y data. Deviations 
may include, but are not limited to, departure from inclusion/exclusio n criteria, dosing, 
duration of treatment, failure to perform the required assessments at specified time points, 
scheduling of visits not in accordance with specifications, or patient safet y.Deviating 
from the protocol is permitted only  if absolutel y nece ssary  for the safet y or clinical 
management of the patient s and must immediately be reported to the S ponsor .
Protocol deviations must be reported to the Sponsor either ver bally or electronically 
within 5 working day s from the day of discovery .
A protocol violation is a form of protocol deviation that has a major impact on the 
patient ’s rights, safet y, or well -being, or on the integrity  and authenticit y of the study 
data.
Protocol viol ations must be reported to the S ponsor within 24 hours, if possible. The 
IRB/IEC must be notified within the time period dictated by  the IRB/ IEC associated with 
this study .  
Forest Laboratories, LLC Page 68 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
10.0 STUDY SPONSORSHIP
10.1 STUDY TERMINATION
The Sponsor reserves the right to terminate the study  in its entiret y or at a specific study  
center before study  comple tion. 
10.2 REPORTING AND PUBLICATION
All data generated in this study  arethe propert y of the S ponsor . An integrated clinical and 
statistical report will be prepared at the completion of the study .
Publication of the results by  the Investigator will be subject to mutual agreement between 
the Investigator and the Sponsor , and will follow Sponsor procedures on publications. 
Forest Laboratories, LLC Page 69 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
11.0 INVESTIGATOR OBLIGAT IONS
11.1 DOCUMENTATION
The Investigator must provide the following to the Sponsor before the start of the study :
A completed and signed Form FDA 1572 ( for US sites). If,during the course of the 
study ,any changes are made that are not reflected on Form FDA 1572, a new Form 
FDA 1572 must be completed and returned to the Sponsor for submission to the FDA
A fully  executed contract
The c urricul avitae for the Investigator and all Sub -Investigators list ed on Form FDA 
1572 (or equivalent) , including a copy of each ph ysician’s license . 
A cop y of the original IRB /ECapproval for conducting the stud y. If the study  is 
ongoing, renewals m ust be submitted at y early intervals . All subsequent 
modifications must be submitted and approved b y the IRB/EC, as stated in 
Section 5.1
A cop y of the IRB /EC-approved ICF
A cop y of the H IPAA authorization form , or other local privacy applicable forms
A list of the IRB/ECmembers or the DHHS general assurance number
A cop y of the laboratory  certifications and reference ranges
The Investigator’s Statement page in this protocol signed and dated b y the 
Investigator
Financial disclosure agreement completed and signed by  the Investigator and all 
Sub-Investigators listed on Form FDA 1572 (or equivalent) . The Investigator and all 
Sub-Investigator s will provide an updated financial disclosure agreement to the 
Sponsor 1 y ear after the completion of the study
11.2 PERFORMANCE
The Investigator must demonstrate reasonable efforts to obtain qualified patient s for the 
study . 
Forest Laboratories, LLC Page 70 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
11.3 USE OF INVESTIGATIONAL MATERIALS
The Investigator will acknowledge that the investigational product supplies are 
investigational and as such must be used strictly  in accordance with the protocol and only  
under the supervision of the Investigator or Sub- Investigators listed on Form FDA 1572
(or equivalent) . The investigational products must be stored in a secure dplace and must 
be locked . At study  initiation ,a Sponsor representa tive,will inventory  the investigational 
products at the site. The Investigator must maintain adequate records documenting the 
receipt and disposition of all study  supplies . The Sponsor will provide a mechanism to 
document receipt and accountability  of inv estigational product .All unused 
investigational products must be returned to the Sponsor . It is the Investigator ’s 
responsibility  to ensure that patient s return their investigational product .
11.4 CASE REPORT FORMS
All patient data relating to the study  will be recorded on eCRF sto be provided by  the 
Sponsor through the EDC sy stem. The Investigator is responsible for verify ing that all 
data entries in the eCRFs are accurate and correct by  electronically  signing the completed 
eCRF casebook submitted to the Sponsor . The Investigator must maintain and retain 
accurate documentation that supports the information entered into the EDC sy stem for 
source document verification and possible regulatory  inspection.
11.5 RETENTION AND REVIEW OF RE CORDS
Records and documents pertaining to the conduct of this study, including case report 
forms, source documents, consent forms, regulatory  documents, clinical laboratory  
results , calibration logs, or reports (including, but not limited to, all local and central 
laboratory  results and ECG reports), and medication inventory  records in all formats 
(including, but not limited to, written, electronic, magnetic, and optical records, and 
scans, x -rays, and ECGs ) must be retained b y the Investigator for a period of at least 
15years after stud y completion unless local regulations or institutional policies require a 
longer retention period or otherwise notified in writing by the Sponsor. 
No study  records shall be destroy ed without notifying the Sponsor and providing the 
Sponsor the opportunity  to arrange long -term storage for such study  records or 
authorizing in writing the destruction of records after the required retention period.
The Investigator must permit access to any  documentation relating to the study  upon 
request of the Sponsor or applicable regulatory  authorities. If the Investigator for the 
study  retires, relocates, or for other reasons withdraws from the responsibility of keeping 
the study  records, custody  must be transferred to a suitable alternate cu stodian employ ee 
of the institution or to a suitably  qualified and responsible third party . The Sponsor must 
be notified in writing of the name and address of the new custodian in advance of the 
transfer. 
Forest Laboratories, LLC Page 71 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
11.6 PATIENT CONFIDENTIALITY
All patient records will on ly be identified by initials and PI Dnumber . Patients’ names are 
not to be transmitted to the Sponsor . The Investigator will keep a m aster patient list on 
which the PI Dnumber and the full name, address, and telephone number of each patient
are listed. 
Forest Laboratories, LLC Page 72 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
12.0 INVESTIGATOR’S STATE MENT
I agree to conduct the study  in accordance with this protocol ( RGH -MD-54
Amendment #2, dated 17Feb2016) and with all applicable government regulations and 
good clinical practice guidance.
_______________________________________ _____/_____/______
Investigator’s Signature Date
_______________________________________
Investigator’s Name 
Forest Laboratories, LLC Page 73 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
13.0 APPENDICES
APPENDIX I. ELEMENTS OF INFORMED CONSENT
Procedures will comply  with 21 CFR, Parts 50 and 312. Signed informed consent will be 
obtained from each patient participating in a clinical research study  or from the patient ’s 
legally  authorized representative . This consent must include the following items:
A statement that the study involves research and an explanation of the purposes of the 
research; a description of the procedures to be followed and the identification of any  
procedures that are experimental; and the expected duration of the patient ’s 
participation
A description of an y reasonably  foreseeable risks or discomforts to the patient
A description of an y benefits to the patient or to others that may  reasonably  be 
expected from the research. If the patient is to be paid for participating in the study , 
the consent form must state the amount that he/she will receive and the schedule of 
payment (to ensure neither coercion nor u ndue influence)
A disclosure of appropriate alternative procedures or courses of treatment, if an y, that 
might be advantageous to the patient
A statement describing the extent, if any , to which confidentiality  of records 
identify ing the patient will be mai ntained and noting the possibility  that the FDA; the 
Sponsor ;the IRB;or an authorized contract research organization may  inspect the 
records
For research involving more than minimal risk, an explanation of whether any  
medical treatment is available if in jury occurs and, if so, what it consists of or where 
further information may  be obtained
An explanation of whom to contact, including the relevant telephone number, for 
answers to pertinent questions about the research and the research patient’s rights and
whom to contact in the event of a research -related injury  to the patient . (Note: I n 
some cases ,it may  be necessary  to identify  a person other than the Investigator as the 
contact . The guidance of the I RB/ECmay be required)
A statement that participation is voluntary , that refusal to participate will involve no 
penalty  or loss of benefits to which the patient is otherwise entitled, and that the 
patient may discontinue participation at any  time without penalty  or loss of benef its to 
which the patient is otherwise entitled 
Forest Laboratories, LLC Page 74 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
A statement that the particular treatment or procedures may  involve risks to the 
patient (or to the embry o or fetus if the patient is, or may  become, pregnant) that are 
at present unforeseeable
The e xpected ci rcumstances forwhich the patient ’s participation may  be terminated 
by the Investigator without regard to the patient’s consent
Any additional costs to the patient that may  result from participation in the research
The consequences of a patient’s decision to withdraw from the research and 
procedures for an orderl y termination of the patient’s participation
A statement that significant new findings developed during the course of the research 
that may  relate to the patient’s willingness to continue participation will be provided 
to the patient
The approximate number of patient s involved in the study
A statement of consent ( e.g., “I agree to participate . ..”)
A place for the patient ’s signature and date of signing
A statement indicating that information about this study  has been, or will be, entered 
into a databank that is publicly  accessible at www.ClinicalTrials.gov.
A cop y of the signed consent form must be given to the patient . 
Forest Laboratories, LLC Page 75 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
APPENDIX II. CONTACT INFORMATION 
Contact information for sponsor personnel is maintained in the Regulatory Binder. 
Forest Laboratories, LLC Page 76 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
APPENDIX III. CONCOMITANT MEDICATI ONS
Medic ations Allowed (Y) and Medications Not Allowed (N) as Concom itant Medications
Drug ClassFrequency of Use
Restrictions Episodic 
(PRN)Chronic
Analgesics Y YNonnarcotic analgesics are allow ed.
Medically appropriate episodic use of 
narcotic analgesics for acute medical 
indications limited to 3 days for an episode 
is allowed
Anesthetics
General N NIf procedures requiring general anesthesia 
are to occur/have occurred, please contact 
the Sponsor Medical Director to report the 
medical condition(s)
Local Y N —
Anorexics N N —
Antacids Y Y —
Antiacne agents Y YTopical agents only, including topical 
antibiotics. Isotretinoin (Accutane) is not
allow ed
Antianginal agents Y Y —
Antiarrhythmics and other 
cardiac agentsN YOnly class II agents (eg, propranolol), 
class IV agents (eg, diltiazem, verapamil), 
and digoxin are allow ed. Dosage must be 
stable for 1 month before screening.
Adenosine, parasympatholytics (atropine) 
and sympathomimetics (epinephrine, 
dopamine) are notallow ed.
Antiasthma agents Y YSystemic steroids are not allowed; inhaled 
steroids at ap proved dosages are allow ed
Antibiotics Y NLinezolid (Zyvox) and Isoniazid are not
allow ed. Clarithromycin, telithromycin, 
chloramphenicol, rifampicin and rifabutin 
are not allow ed.
Anticonvulsants N N
Anticoagulants N N Warfarin (Coumadin) is not allow ed
Anticonvulsants N N —
Antidepressants N N —
Antidiarrheal agents Y NOnly loperamide (Imodium), bismuth 
subsalicylate (Pepto -Bismol), and kaolin 
preparations are allow ed 
Forest Laboratories, LLC Page 77 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
Medic ations Allowed (Y) and Medications Not Allowed (N) as Concom itant Medications
Drug ClassFrequency of Use
Restrictions Episodic 
(PRN)Chronic
Antiemetics/Antinauseants Y NAntidopaminergic agents (such as 
metoclopramide and phenothiazines), 
domperidone, scopolamine, 5 -HT3 receptor 
antagonists (eg, ondansetron) and sedating 
(H1) antihistamines are not allow ed. 
Phosphoric acid preparations (Emetrol, 
Emecheck), bismuth subsalicylate 
(Pepto -Bismol), and cola syrup are allow ed.
Antifungal agents
Systemic N N —
Topical Y Y —
Antihistamines Y YSedating (H1) antihistamines are not 
allow ed. Only Allegra (fexofenadine), 
Zyrtec (cetirizine), Xyzal (levocetirizine), 
Claritin (loratadine), and Clarinex 
(desloratadine) are allow ed for episodic or 
chronic use. Combination products 
containing the word nighttime or some 
synonym routinely include a sedating 
antihistamine and are not allowed (see 
Cough/cold Preparations for combination 
products). Terf enadine is not allow ed.
Antihypertensives N YDiupres (chlorothiazide and reserpine), 
clonidine (Catapres), guanabenz 
(Wytensin), guanfacine (Tenex), 
guanethidine (Ismelin), methyldopa 
(Aldomet), direct vasodilators (hydralazine, 
minoxidil), sodium nitroprusside, 
nitroglycerin, and diazoxide are not 
allow ed. For all others (β -blockers, calcium 
channel blockers, ACE inhibitors, etc) the 
medication and dosage should be stable for 
1 month before screening
Anti-impotence medications Y Y —
Anti-inflammatory drugs Y YIndom ethacin and systemic corticosteroids 
are not allow ed
Antimigraine Y NTriptans allowed. Ergotamine or ergot 
derivatives are not allowed. Narcotics, 
antidepressants, and anticonvulsants are not 
allow ed
Antineoplastics N N — 
Forest Laboratories, LLC Page 78 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
Medic ations Allowed (Y) and Medications Not Allowed (N) as Concom itant Medications
Drug ClassFrequency of Use
Restrictions Episodic 
(PRN)Chronic
Antiobesity drugs/appetite 
suppressantsN N —
Antiplatelet agents N YAspirin (maximum dosage of 325mg/day) 
and clopidogrel (Plavix) are allow ed
Antipsoriatic treatments Y Y Acitretin (Soriatane) is not allowed
Antiparkinsonian drugs N NDopamine -releasing drugs, dopamine 
agonists, amantadine, levodopa, and 
monoamine oxidase –B inhibitors are not 
allow ed. For extrapyramidal symptoms, 
diphenhydramine (50 mg/day) and 
benztro pine (up to 4 mg/day or up to 
2mg/day, if given parenterally) are al lowed 
(see S ection 9.4.8 ). Propranolol may also be 
used for treatment of akathisia
Antipsychotics N N —
Antismoking medications N NVarenicline (Chantix) is not allow ed.
Nicotine replacement therapies are allowed
Antiviral agents Y YThe follow ing agents are allowed: 
acyclovir, famciclovir, valacyclovir, 
penciclovir, docosanol, trifluridine, and 
vidarabine. Amantadine and rimantadine are 
not allow ed. Interferons are not allow ed
Anxiolytics Y NLorazepam or it s equivalent benzodiazepine 
may be prescribed as rescue medication for 
agitation, restlessness ,or hostility . Episodic 
use of lorazepam up to 2 mg/day (or 
equivalent) and for up to 3 consecutive 
days at a time is allowed for agitation, 
restlessness, and ho stility.
Lorazepam or other benzodiazepines may 
not be used in the 8 hours before any 
behavioral assessments. Diazepam may not 
be used in the 24 hours before any 
behavioral assessments . 
Forest Laboratories, LLC Page 79 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
Medic ations Allowed (Y) and Medications Not Allowed (N) as Concom itant Medications
Drug ClassFrequency of Use
Restrictions Episodic 
(PRN)Chronic
Cough/cold preparations Y NCough preparations containing 
dextromethorphan or narcotics are not 
allow ed. Decongestant preparations 
containing pseudoephedrine or 
phenylpropanolamine are not allow ed. 
Phenylephrine nasal sprays are allow ed for 
brief medically appropriate use for up to 
5days (also see Antihistamines )
Diuretics N YMedication and dosage must be stable for 
1month before screening
Drugs used to treat 
constipationY N**Bulk laxatives, emollient laxatives are 
allow ed
Episodic use of stimulant laxatives 
containing senna, bisacodyl, and 
anthraquinone derivatives is allow ed. 
Osmotic laxatives such as oral magnesium 
hydroxide (milk of magnesia), oral sodium 
citrate and sodium biphosphate are allow ed. 
Hyperosmotic laxatives such as sorbitol, 
lactulose, and polyethylene glycol are not 
allow ed
Gastrointes tinal:
H2-blockers/
proton pump inhibitors/
prokinetic agentsY YCimetidine (Tagamet) is not allow ed.
Metoclopramide and cisapride are not 
allow ed
Hormones N YThyroid hormone replacement is allow ed. 
Therapeutic use in psychiatric disorders 
(eg,T3 augmentation therapy) is not 
allow ed. Dosage of thyroid medication must 
be stable for 1 month before screening.
Systemic contraceptives (oral contraceptives 
of estrogen and progestin combinations, 
contraceptive implants such as 
Depo -Provera and Norplant, o r 
transdermally delivered contraceptives such 
as Ortho Evra) are allow ed but must be 
stable for 1 month before screening
Hormone suppressants N YOnly Proscar (finasteride) and Avodart 
(dutasteride) are allow ed. Dosage must be 
stable for 3 months before screening 
Forest Laboratories, LLC Page 80 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
Medic ations Allowed (Y) and Medications Not Allowed (N) as Concom itant Medications
Drug ClassFrequency of Use
Restrictions Episodic 
(PRN)Chronic
Hypoglycemic agents N YOral hypoglycemic agents are allow ed, 
except the strong CYP3A inducers 
pioglitazone and troglitazone are not 
allow ed. Chronic use of insulin is allowed. 
Consult Study Physician for episodic use of 
insulin. Dosage must be stable for 1 month 
before screening
Hypolipidemics N YStatins (lovastatin, pravastatin, simvastatin, 
atorvastatin, fluvastatin, rosuvastatin), 
fibrates (gemfibrozil, fenofibrate), and 
ezetimibe are allow ed. Dosage must be 
stable for 1 month before screening. The 
Study Physician must be consulted for 
combined use of hypolipidemic agents. Bile 
sequestrants are not allowed. Niacin and 
niacinamide may be allowed if patient has 
taken these agents chr onically ≥12months
Mood stabilizers N N —
Muscle relaxants N N —
Psychotropic drugs not 
otherwise specified 
(including herbal products)N NNo drugs with psychomotor effects or with 
anxiolytic, stimulant, antipsychotic, or 
sedative properties are allow ed. 
Herbal/dietary products and supplements 
with potential psychoactive actions 
including St. John’s wort, kava kava, 
SAMe, valerian root, DHEA, tyrosine, and 
5-HTP are not allow ed
Sedatives/hypnotics Y YZolpidem extended release (maximum of 
12.5 mg/day), zolpidem (maximum of 
10mg/day), zaleplon (maximum of 
20mg/day), chloral hydrate (maximum 
of 1000 mg/day), and eszopiclone
(maximum of 3 mg/day) are allow ed for 
sleep. Sedatives/hypnotics may not be used 
in the 8 hours before any behavioral 
assessments
Steroids
Systemic N N —
Topical Y Y —
Inhalant Y Y —
Intra -articular Y NA — 
Forest Laboratories, LLC Page 81 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
Medic ations Allowed (Y) and Medications Not Allowed (N) as Concom itant Medications
Drug ClassFrequency of Use
Restrictions Episodic 
(PRN)Chronic
Stimulants N NOral or transdermal methylphenidate, 
amphetamine products or prodrugs, 
pseudoephedrine, modafinil (Provigil), and 
armodafinil (Nuvigil) are not allow ed
Vaccines Y NA —
N =not allowed; NA = not applicable; PRN =as needed; Y =yes, allowed 
Forest Laboratories, LLC Page 82 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
APPENDIX IV. MONTGOMERY -ÅSBERG DEPRESSION RATING SCALE
Montgom ery Åsberg Depression Rating Scale (MADRS)
The rating should be based on a clinical interview moving from broadly  phrased 
questions about sy mptoms to more detailed ones which allow a precise rating of severi ty. 
The rater must decide whether the rating lies on predefined scale steps (0, 2, 4, 6) or 
between them (1, 3, 5).
It is important to remember that it is only  on rare occasions that a depressed patient is 
encountered who cannot be rated on the items in th e scale. If definite answers cannot be 
elicited from the patient all relevant clues as well as information from other sources 
should be used as a basis for the rating in line with customary  clinical practice.
The scale may  be used for any  time interval between ratings, be it weekly  or otherwise, 
but this must be recorded.
Item List
1. Apparent sadness
2. Reported sadness
3. Inner tension
4. Reduced sleep
5. Reduced appetite
6. Concentration difficulties
7. Lassitude
8. Inability to feel
9. Pessimistic thoughts
10. Suicidal thoughts 
Forest Laboratories, LLC Page 83 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
1. Apparent Sadness
Representing despondency, gloom and despair, (more than just ordinary transient low 
spirits) reflected in speech, facial expression, and posture. Rate by depth and inability to 
brighten up.
0 No sadness.
1
2 Looks dispirited but does brig hten up without difficulty.
3
4 Appears sad and unhappy most of the time.
5
6 Looks miserable all the time. Extremely despondent.
2. Reported sadness
Representing reports of depressed mood, regardless of whether it is reflected in 
appearance or not. Includes low spirits, despondency or the feeling of being beyond help 
and without hope. Rate according to intensity, duration and the extent to which the mood 
is reported to be influenced by events.
0 Occasional sadness in keeping with the circumstances.
1
2 Sad or low but brightens up without difficulty.
3
4 Pervasive feelings of sadness or gloominess. The mood is still influenced by 
external circumstances.
5
6 Continuous or unvarying sadness, misery or despondency. 
Forest Laboratories, LLC Page 84 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
3. Inner tension
Representing feeling of i ll-defined discomfort, edginess, inner turmoil, mental tension 
mounting to either panic, dread or anguish. Rate according to intensity, frequency, 
duration and the extent of reassurance called for.
0 Placid. Only fleeting inner tension.
1
2 Occasional feel ings of edginess and ill -defined discomfort.
3
4 Continuous feelings of inner tension or intermittent panic which the patient can 
only master with some difficulty.
5
6 Unrelenting dread or anguish. Overwhelming panic.
4. Reduced sleep
Representing the exper ience of reduced duration or depth of sleep compared with the 
subject’s own normal pattern when well.
0 Sleeps as usual.
1
2 Slight difficulty dropping off to sleep or slightly reduced, light or fitful sleep.
3
4 Sleep reduced or broken by at least two hours.
5
6 Less than two or three hours sleep. 
Forest Laboratories, LLC Page 85 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
5. Reduced appetite
Representing the feeling of a loss of appetite compared with when well. Rate by loss of 
desire for food or the need to force oneself to eat.
0 Normal or increased appetite.
1
2 Slightly re duced appetite.
3
4 No appetite. Food is tasteless.
5
6 Needs persuasion to eat at all.
6. Concentration difficulties
Representing difficulties in collecting one’s thoughts mounting to incapacitating lack of 
concentration. Rate according to intensity, fre quency, and degree of incapacity produced.
0 No difficulties in concentrating.
1
2 Occasional difficulties in collecting one’s thoughts.
3
4 Difficulties in concentration and sustaining thought which reduces ability to read 
or hold a conversation.
5
6 Unable to read or converse without great difficulty. 
Forest Laboratories, LLC Page 86 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
7. Lassitude
Representing a difficulty getting started or slowness initiating and performing 
everyday activities.
0 Hardly any difficulty in getting started. No sluggishness.
1
2 Difficulties in starting activities.
3
4 Difficulties in starting simple routine activities which are carried out with effort.
5
6 Complete lassitude. Unable to do anything without help.
8. Inability to feel
Representing the subjective experience of reduced interest in the surrou ndings, or 
activities that normally give pleasure. The ability to react with adequate emotion to 
circumstances or people is reduced.
0 Normal interest in the surroundings and in other people.
1
2 Reduced ability to enjoy usual interests.
3
4 Loss of intere st in the surroundings. Loss of feelings for friends and 
acquaintances.
5
6 The experience of being emotionally paralyzed, inability to feel anger, grief or 
pleasure and a complete or even painful failure to feel for close relatives and 
friends. 
Forest Laboratories, LLC Page 87 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
9. Pessimi stic thoughts
Representing thoughts of guilt, inferiority, self- reproach, sinfulness, remorse
and ruin.
0 No pessimistic thoughts.
1
2 Fluctuating ideas of failure, self -reproach or self -depreciation.
3
4 Persistent self -accusations, or definite but still rational ideas of guilt or sin. 
Increasingly pessimistic about the future.
5
6 Delusions of ruin, remorse or unredeemable sin. Self -accusations which are 
absurd and unshakable.
10. Suicidal thoughts
Representing the feeling that life is not worth living, that a natural death would be 
welcome, suicidal thoughts and preparations for suicide.
Suicidal attempts should not in themselves influence the rating.
0 Enjoys life or takes it as it comes.
1
2 Weary of life. Only fleeting suicidal thoughts.
3
4 Probably better off dead. Suicidal thoughts are common and suicide is considered 
as a possible solution, but without specific plans or intention.
5
6 Explicit plans for suicide when there is an opportunity. Active preparations for 
suicide.
© 1979 The Royal College of Psychiatrists. Montgomery, S.A. & Åsberg, M. (1979). A new 
depression scale designed to be sensitive to change. British Journal of Psychiatry , 134, 382-389. 
Written permission must be obtained from the Royal College of Psychiatrists for copying and 
distribution to others or for republication (in print, online or by any other medium). 
Forest Laboratories, LLC Page 88 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
  
Forest Laboratories, LLC Page 89 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
  
 
 
 
 
)RUHVW/DERUDWRULHV//& 3DJHRI
)HE$PHQGHG3URWRFRO5*+0'$PHQGPHQW
82
)RUHVW/DERUDWRULHV//& 3DJHRI
)HE$PHQGHG3URWRFRO5*+0'$PHQGPHQW
 
  
Forest Laboratories, LLC Page 92 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

28
)RUHVW/DERUDWRULHV//& 3DJHRI
)HE$PHQGHG3URWRFRO5*+0'$PHQGPHQW
29
)RUHVW/DERUDWRULHV//& 3DJHRI
)HE$PHQGHG3URWRFRO5*+0'$PHQGPHQW
APPENDIX VII. CLINICAL GLOBAL IMPR ESSION S–SEVERITY
SEVERITY	OF	ILLNESS
Considering your total clinical experience with this population, how mentally  ill is the 
patient at this time?
Check one:
1 = Normal, not at all ill
2 =Borderline ill
3 =Mildly  ill
4 =Moderately  ill
5 =Markedl y ill
6 =Severely  ill
7 =Among the most extremely  ill patients 
Forest Laboratories, LLC Page 95 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
 
Forest Laboratories, LLC Page 96 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
Forest Laboratories, LLC Page 97 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
Forest Laboratories, LLC Page 98 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
Forest Laboratories, LLC Page 99 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

Pg. 1 of 2 
Forest Laboratories, LLC Page 100 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
Forest Laboratories, LLC Page 101 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
 
 
 
 
 
 
 
 
 
 
  
Forest Laboratories, LLC Page 102 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
 
 
 
 
 
 
 
 
 
  
Forest Laboratories, LLC Page 103 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
 
 
 
 
 
 
 
 
 
 
 
  
Forest Laboratories, LLC Page 104 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
Forest Laboratories, LLC Page 105 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
Forest Laboratories, LLC Page 106 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
Forest Laboratories, LLC Page 107 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
Forest Laboratories, LLC Page 108 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
Forest Laboratories, LLC Page 109 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
 
 
 
 
 
 
 
  
Forest Laboratories, LLC Page 110 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
Forest Laboratories, LLC Page 111 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
Forest Laboratories, LLC Page 112 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
Forest Laboratories, LLC Page 113 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
 
 
 
 
 
  
Forest Laboratories, LLC Page 114 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
Forest Laboratories, LLC Page 115 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
Forest Laboratories, LLC Page 116 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

 
Forest Laboratories, LLC Page 117 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2

14.0 LITERATURE CITED
Altshuler LL, Gitlin MJ, Mintz J, et al. Subsy ndromal depression is associated with 
functional impairment in patients with bipolar disorder. J Clin Psy chiatry  
2002; 63:807 -11.
American Ps ychiatric Association. Diagnostic and statistical manual of mental disorders, 
Fifth Edition . Washington, DC: American Ps ychiatric Association; 2013.
Barnes TRE. A rating scale for drug -induced akathisia. Br J Psy chiatry  1989; 154:672-6.
Berk M, Dodd S, Kauer -Sant’anna M, et al. Dopamine dy sregulation sy ndrome: 
implications for a dopamine hy pothesis of bipolar disorder. Acta Psy chiatr Scand 
Suppl 2007;434:41 -9.
Calabrese JR, Hirschfeld RM, Reed M, et al. I mpact of bipolar disorder on a U S 
community  sample. J Clin Psy chiatry  2003; 64:425 -32.
Calabrese JR, Hirschfeld RM, Fry e MA, et al. Impact of depressive s ymptoms compared 
with manic sy mptoms in bipolar disorder: results of a US community -based sample. 
JClin Psy chiatry 2004; 65:1499 -504.
Calabrese JR , Keck PE Jr ,Macfadden W, et al.A randomized, double -blind, placebo -
controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J 
Psychiatry 2005; 162(7):1351-60.
Chen X, L uo X, Capizzi T. The application of enhanced parallel gatekeeping strategies. 
Statist Med 2005 ;24:1385-97.
Dilsaver SC, Chen YW, Swann AC, et al. Suicidality , panic disorder and psy chosis in 
bipolar depression, depressive -mania and pure- mania. Psy chiatry  Res 1997 Nov 14;73 
(1-2):47-56. 
Goodwin FK, Jamison KR. Treatment. In: Manic -depressive illness. New York: Oxford 
University  Press; 1990. p. 642 -7.
Guy W, editor. ECDEU Assessment Manual for Psy chopharmacology . DHEW 
publication, no. (ADM) 76-338. Rockville, MD: US. Dep t of Health, Education, and 
Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health 
Administration, National I nstitute of Mental Health, Psy chopharmacology  Research 
Branch, Division of Extramural Research Programs; 1976;218-22.
Hamilton M. T he assessment of anxiety  states b y rating. Br J Med Psychol 1959;32:50 -5. 
Forest Laboratories, LLC Page 118 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
Hamilton M. A rating scale for depression. J Neurol Neurosurg Ps ychiat 
1960; 32(1) :56-62.
Hamilton M. Development of a rating scale for primary  depressive illness. Br J Soc Clin 
Psychol 1967;6:278 -96.
Hlastala SA, Frank E, Mallinger AG, et al. Bipolar depression: an underestimated 
treatment challenge. Depress Anxiety  1997; 5:73-83.
Judd LL, Akiskal HS, Schettler PJ, et al. The long- term natural history  of the weekl y 
symptomatic status of bipolar I disorder. Arch Gen Psy chiatry  2002; 59:530 -7.
Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural 
history  of the long -term weekl y symptomatic status of bipolar II disorder. Arch Gen 
Psychiatry  2003; 60:261 -9.
Keller MB, Lavori PW, Cory ell W, et al. Differential outcome of pure manic, 
mixed/cy cling, and pure depressive episodes in patients with bipolar illness. JAMA
1986; 255:3138-42.
Kenward MG, Molenberghs G, Thijs H. Pattern -mixture models with proper time 
depende nce. Biometrika 2003; 90(1):53-71.
Kessler RD, Chiu WT, Demler O, et al. Prevalence, severit y, and comorbidity  of 
12-month DSM -IV disorders in the National Comorbidity  Survey  Replication. Arch Gen 
Psychiatry  2005; 62:617 -27.
Leggio GM, Micale V, Drago F. Increased sensitivity  to antidepressants of D3 dopamine 
receptor -deficient mice in the forced swim test (FST). Eur Neur opsychopharmacol
2008;18:271 -7.
Leverich GS, Altshuler LL, Fry e MA, et al. Factors associated with suicide attempts in 
648 patients with bipolar disorder in the Stanley  Foundation Bipolar Network. J Clin 
Psychiatry  2003; 64:506 -15.
MacQueen GM, Young LT, Joffe RT. A review of psy chosocial outcome in patients with
bipolar disorder. Acta Psychiatr Scand 2001; 103:163 -70.
Montgomery  SA, Asberg M. A new depression scale designed to be sensitive to change. 
Br J Psy chiatry  1979; 134:382 -9.
Muller -Oerlinghausen B, Berghöfer A, Bauer M. Bipolar disorder. Lancet 
2002;359:241-7. 
Forest Laboratories, LLC Page 119 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
Post RM, Denicoff KD, Leverich GS, et al. Morbidity  in 258 bipolar outpatients followed 
for 1 year with daily prospective ratings on the NIMH life chart method. J Clin 
Psychiatry  2003; 64:680 -90.
Post RM. The impact of bipolar depression. J Clin Psy chiatry  2005;66(Suppl 5)5 -10.
RGH -188 (cariprazine). Investigator’s brochure. Edition 11. Jersey  City, NJ: Fore st 
Laboratories, LLC ; 2015 Nov.
Rush JA, Trivedi MH, I brahim HM, et al. The 16 -item Quick I nventory  of Depressive 
Symptomatology  (QIDS), Clinician Rating (QIDS -C), and Self -Report (QIDS -SR): A 
psychometric evaluation in patients with chronic major depression. Biol Psy chiatry  
2003;573-83.
Simpson GM, Angus JW. A rating scale f or extrapy ramidal side effects. Acta Psy chiatr 
Scand Suppl 1970;212:11 -9.
Steiner H, Fuchs S, Accili D. D3 dopamine receptor -deficient mouse: evidence for
reduced anxiety . Phy siol Behav 1997 ;63:137 -41.
Study  RGH -MD-52: A double -blind placebo -controlled eva luation of RGH -188 
(cariprazine) in bipolar depression. Jersey  City , NJ: Forest Research Institute, I nc.; 
2011 May 09.
Study  RGH -MD-56: A double -blind placebo -controlled evaluation of the safet y and 
efficacy  of cariprazine in patients with bipolar depress ion.Jersey  City, NJ: Forest 
Research Institute, Inc.; 2014 Oct09
Suppes T, Datto C, Minkwitz M, et al . Effectiveness of the extended release formulation 
of quetiapine as monotherap y for the treatment of acute bipolar depression. J Affect 
Disord 2010; 121(1 -2):106 -15. 
Thase M, Macfadden W, Weisler RH, et al. Efficacy  of quetiapine monotherapy  in 
bipolar I and IIdepression: a double -blind, placebo -controlled study  (The BOLDER II 
Study ). J Clin Psy chopharmacol. 2006; 27(1):51. 
Tohen M, Vieta E , Calabrese J, et al. Efficacy  of olanzapine and olanzapine -fluoxetine 
combination in the treatment of bipolar I depression. Arch Gen Ps ychiatry 2003; 
60(11):1079-88.
World Health Organization. World health report 2001―mental health: new 
understanding, new hope. Available from: http://www.who.int/whr/2001/en/. Accessed
2011 Jan19. 
Forest Laboratories, LLC Page 120 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
Wyatt RJ, Henter L . An economic evaluation of manic -depressive illness―1991. Soc 
Psychiatry  and Psy chiatr Epidemiol 1995; 30:213 -9.
Young RD, Briggs JT, Ziegler VE, et al. A rating scale for mania: reliabilit y, validity  and 
sensitivity . Brit J Psy chiat 1978;33:429 -35. 
Forest Laboratories, LLC Page 121 of 121
17 Feb 2016Amended Protocol RGH-MD-54 Amendment 2
Forest Laboratories, LLC, an Allergan Affiliate
Harborside Financial Center, Plaza V
Jersey City, NJ 07311
SUMMARY OF CHANGES TO PROTOCOL 
RGH -MD-54, A PHASE 3, RANDOMIZED, DOUBLE- BLIND, 
PLACEBO -CONTROLLED, PARALLEL- GROUP, MULTICENTER, 
FIXED- DOSE CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY 
AND TOLERABILITY OF CARIPRAZINE IN PATIENTS WITH BIPOLAR I 
DEPRESSION
Amendment #2, 17 Feb2016
IND #77, 726
Original Protocol Date: 12Nov 2015
Protocol Amendment #1:02 Feb 2016
Confidentiality Statement
This document is the property of Forest Laboratories, LLC, an Allergan Affiliate, and 
may not —in full or part —be passed on, reproduced, published, distributed, or submitted 
to any regulatory authority without the express written permission of Forest 
Laboratories, LLC. 
Forest Laboratories, LLC Page 1 of 6
17 Feb 2016Protocol RGH-MD-54 Amendment 2
1.0 INTRODUCTION
Amendment #2 specifies the following change to RGH- MD-54Protocol Amendment #1, 
dated 02 Feb 2016: 
  
The page and protocol section numbers in the headings of this amendment are those of 
the previous version of the protocol.  
Forest Laboratories, LLC Page 2 of 6
17 Feb 2016Protocol RGH-MD-54 Amendment 2

2.0 GLOBAL CHANGES
The following changes have been made globall y to the protocol:
None 
Forest Laboratories, LLC Page 3 of 6
17 Feb 2016Protocol RGH-MD-54 Amendment 2
3.0 SECTIONS DELETED
The following sections have been removed from the protocol:
None 
Forest Laboratories, LLC Page 4 of 6
17 Feb 2016Protocol RGH-MD-54 Amendment 2
4.0 SECTIONS ADDED
None 
Forest Laboratories, LLC Page 5 of 6
17 Feb 2016Protocol RGH-MD-54 Amendment 2
5.0 REVISIONS
 
 
 
 
 
 
 
  
Forest Laboratories, LLC Page 6 of 6
17 Feb 2016Protocol RGH-MD-54 Amendment 2
